

tivity was also as high as 100% on screening for EBV genome or telomerase activity from swabs and amounted to 81.2% when both EBV and telomerase were simultaneously assessed. Six and 8 of 27 non-NPC swabs were positive for EBV genome and telomerase activity, respectively. Only 2 cases of non-NPC swabs showed both EBV DNA and telomerase activity. These 2 cases, acute rhinitis and sinusitis, also presented with inflammation. This suggests that the specificity on combination of both techniques was 92.6% and could be as high as 100% when analyzing only patients without signs and symptoms of inflammation.

DISCUSSION

Screening to obtain early and definite diagnoses of NPC is an important issue among high-risk populations. For countries with intermediate risk, such as Thailand, this population includes middle- or advanced-aged men of Chinese origin or siblings of patients with the tumor.¹ At present, the screening method most commonly available is based on anti-EBV serology. Nevertheless, the specificity of this method is low, especially when the cut-off point is set at a low level to increase the sensitivity. Consequently, cancer develops in only a few positive cases. In addition, a substantial proportion of patients with subclinical NPC would not be detected with conventional nasopharyngeal examination. For identification of such patients, endoscopy and multiple biopsy specimens of the nasopharynx have proved to be an effective method for diagnosing submucosal growth of NPC.²⁶

Because virtually all cases of NPC are associated with EBV, a number of studies identified the EBV genome from nasopharyngeal epithelium with noninvasive methods such as wash, swab, and brush biopsy. The purpose of such studies was to help improve sensitivity and specificity for NPC screening and early diagnosis. In addition, these techniques may help reduce the number of multiple nasopharyngeal biopsies, which are invasive techniques. However, those studies showed different results with normal controls. Approximately 81%, 35%, and 47% of normal populations from Greenland, Denmark, and Taiwan, respectively, were found to be positive for EBV DNA from throat washes.¹³⁻¹⁴ Twenty-five percent of normal cases in Taiwan were positive by nasopharyngeal swab.¹⁵ Interestingly, only 2 of 157 control cases were positive for EBV DNA when brush biopsy was performed among Chinese immigrants in North America.¹⁶ Our study used nested PCR of nasopharyngeal swabs from Thai patients and identified EBV in 6 of 27 cases. On the contrary, nasopharyngeal swab and brush biopsy showed higher frequencies of detecting the EBV genome from NPC than the wash.¹³⁻¹⁶ These data suggested EBV in the throat could be iden-

tified from 2 sources. The first source is premalignant or early lesions of NPC. The second is chronic EBV infection. As a result, use of the EBV genome as a marker for identifying NPC exfoliated cells should yield a wide range of sensitivity and specificity depending on the methods and source of specimens.

Telomerase is a good candidate marker for cancer screening because it is usually expressed in most cancers, including NPC, but not in most normal tissues.^{18,19} These data were confirmed in this study because 93.7% of NPC biopsy specimens were positive. Our recent studies performed among stratified squamous epithelial tissues, such as oral epithelium and cervix, indicated that telomerase activity is associated not only with cancer development but also with certain benign conditions (especially with inflammation), such as lichen planus.²⁰⁻²² This may cause false-positive results when telomerase is used as a marker to screen cancer from squamous cell origin, including NPC. However, because the mechanism causing false-positive results is distinct compared with identifying the EBV genome and telomerase, combination of both markers should improve sensitivity and specificity for NPC diagnosis from nasopharyngeal exfoliated cells. Telomerase assay and nested PCR showed high sensitivity and specificity when applied to nasopharyngeal swabs. On combination of both techniques, the sensitivity was improved to 100% if either one of the positive results was counted, and the specificity was 92.6% if both positive results were analyzed together.

CONCLUSION

Analyzing NPC markers from nasopharyngeal exfoliated cells with a method such as swab could help improve diagnosis, especially for cancer screening and early diagnosis. As different frequencies of EBV genome detection were reported between normal controls, depending on the methods applied and the source of cases, an additional marker should be helpful for identifying NPC cells. Telomerase activity, according to this study, is a good candidate for use in conjunction with nested PCR for detection of the EBV genome. Because the sensitivity was 100% when counting either positive result obtained by these techniques, only high-risk populations with either EBV genome or telomerase activity identified from nasopharyngeal swabs should be indicated for multiple biopsies. More case control studies, especially from subclinical NPC, should be performed to indicate the sensitivity of nested PCR and TRAP assay when applied to this group.

We thank the staff of the Department of Otolaryngology and the Radiotherapy Section, Department of Radiology, Faculty of Medicine, Chulalongkorn University, and National

Cancer Institute (Thailand), for the recruitment of patients and collection of materials. We also thank Ms Petra Hirsh for critical review of the manuscript.

REFERENCES

1. Saseo AJ. Screening of undifferentiated carcinoma of the nasopharynx. *Bull Cancer* 1996;83:344-51.
2. Vatanasapt V, Martin N, Sriplung H, et al. Cancer incidence in Thailand, 1988-1991. *Cancer Epidemiol Biomarkers Prev* 1995;4:475-83.
3. Muir CS. Nasopharyngeal carcinoma in non-Chinese populations with special reference to south-east Asia and Africa. *Int J Cancer* 1971;8:351-63.
4. Sumitsawan Y, Loryidhaya V, Martin N. Carcinoma of the nasopharynx in Chiang Mai University Hospital: a review of 205 cases. *J Med Assoc Thai* 1990;73:450-7.
5. Mutirangura A, Tanunyuthawongse C, Pongthanasakem W, et al. Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. *Br J Cancer* 1997;76:770-6.
6. Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. *Lancet* 1997;350:1087-91.
7. Desgranges C, Wolf H, De-The G, et al. Nasopharyngeal carcinoma. X. Presence of Epstein-Barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya. *Int J Cancer* 1975;16:7-15.
8. Pearson GR, Weiland LH, Neel HB 3d, et al. Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. *Cancer* 1983;51:260-8.
9. Zeng Y, Zhang LG, Wu YC, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. *Int J Cancer* 1985;36:545-7.
10. Zong YS, Sham JS, Ng MH, et al. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. *Cancer* 1992;69:3-7.
11. Liu MY, Chang YL, Ma J, et al. Evaluation of multiple antibodies to Epstein-Barr virus as markers for detecting patients with nasopharyngeal carcinoma. *J Med Virol* 1997;52:262-9.
12. Sheen TS, Ko JY, Chang YL, et al. Nasopharyngeal swab and PCR for the screening of nasopharyngeal carcinoma in the endemic area: a good supplement to the serologic screening. *Head Neck* 1998;20:732-8.
13. Hording U, Albeck H, Katholm M, et al. Epstein-Barr virus in exfoliated cells from the postnasal space. Viral detection by polymerase chain reaction is not a useful means of screening for nasopharyngeal carcinoma in high-risk populations. *APMIS* 1994;102:367-70.
14. Jeng KC, Hsu CY, Liu MT, et al. Prevalence of Taiwan variant of Epstein-Barr virus in throat washings from patients with head and neck tumors in Taiwan. *J Clin Microbiol* 1994;32:28-31.
15. Tine CL, Liavaag PG, Freeman JL, et al. Nasopharyngeal brush biopsies and detection of nasopharyngeal cancer in a high-risk population. *J Natl Cancer Inst* 1999;91:796-800.
16. Rhyu MS. Telomeres, telomerase, and immortality. *J Natl Cancer Inst* 1995;87:881-94.
17. Kim NW, Pratszyk MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. *Science* 1994;266:2011-5.
18. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. *Eur J Cancer* 1997;33:787-91.
19. Cheng RY, Yuen PW, Nicholls JM, et al. Telomerase activation in nasopharyngeal carcinoma. *Br J Cancer* 1998;77:456-60.
20. Mutirangura A, Supriyaphun P, Tirrekanon S, et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. *Cancer Res* 1996;56:3530-3.
21. Mutirangura A, Sriuranpong V, Termungtraungler W, et al. Telomerase activity and human papillomavirus in malignant, premalignant and benign cervical lesions. *Br J Cancer* 1998;78:933-9.
22. Thongprasom K, Mutirangura A, Cheerat S. Telomerase activity in oral lichen planus. *J Oral Pathol Med* 1998;27:395-8.
23. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). *Nucleic Acids Res* 1997;25:2595-7.
24. Shotelersuk K, Khorprasert C, Sakdikul S, et al. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. *Clin Cancer Res* 2000;6:1046-51.
25. Resnick RM, Cornelissen MT, Wright DK, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. *J Natl Cancer Inst* 1990;82:1477-84.
26. Sham JS, Wei WI, Zong YS, et al. Detection of subclinical nasopharyngeal carcinoma by fiberoptic endoscopy and multiple biopsy. *Lancet* 1990;335:371-4.

Epstein-Barr Virus DNA in Serum/Plasma as a Tumor Marker for Nasopharyngeal Cancer¹

Kanjana Shotelersuk,² Chonlakit Khorprasert,²
Sairoong Sakdikul, Wichai Pornthanakasem,
Narin Voravud, and Apiwat Mutirangura³

Radiotherapy Section, Department of Radiology [K. S., C. K.], Genetics Unit, Department of Anatomy [S. S., A. M.], Department of Microbiology [W. P.], and Medical Oncology Unit, Department of Medicine [N. V.], Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

ABSTRACT

Nasopharyngeal cancer (NPC) constitutes a type of carcinoma encountered frequently in Southern China, among Eskimos of the Arctic region, and to a lesser extent in Southeast Asia. Because EBV DNA present in plasma or serum of NPC patients has proven to represent a promising noninvasive tumor marker, the present study was designed to determine the incidence of serum/plasma EBV DNA by nested PCR during various disease management stages. By this method, we could detect EBV DNA in plasma/serum of 98 of 167 NPC patients prior to treatment, compared with 10 of 77 samples derived from healthy blood donors serving as controls, with a similar prevalence observed in plasma *versus* serum. Investigation of 13 patients subjected to radiotherapy revealed plasma EBV DNA to persist in the plasma of one case, whereas among the remaining patients, it had vanished during the early phase of treatment. Finally, with 52 samples derived from 37 NPC patients during follow-up, we established 100% specificity and 0% false-positive rate for plasma DNA detection by nested PCR. Moreover, we subjected 24 known EBV DNA-positive serum samples to DNase digestion prior to DNA extraction and amplification to differentiate between free and encapsulated viral DNA, which demonstrated complete absence of the human β -globin genomic DNA in contrast to EBV DNA detectable in 14 samples. In conclusion, applying this noninvasive method, serum/plasma EBV DNA constitutes a reliable tumor marker prior to, during, and after treatment of NPC.

INTRODUCTION

The discovery of tumor-derived DNA in the circulation of cancer patients raises the possibility of a new strategy for noninvasive cancer detection and monitoring (1-3). In NPC,⁴ we have previously demonstrated that EBV DNA is not only detectable in tumor tissue but is also detectable in the patients' cell-free sera (4). In addition, comparison between EBV typing of primary tumors and their sera showed identical results, suggesting that serum EBV DNA represents tumor DNA. In a recent study, Lo *et al.* (5) have further explored this issue with respect to sensitivity and quantity of the plasma EBV DNA derived from NPC patients. A very high incidence of plasma EBV DNA was shown prior to treatment. Furthermore, the presence of plasma EBV DNA 1 month after completion of radiotherapy was associated with the disease persisting, either because of partial response or distant metastasis. Hence, serum/plasma EBV DNA represents a promising tumor marker for noninvasive cancer detection and monitoring of NPC.

NPC constitutes an important cancer in Asia encountered frequently in Southern China and among Eskimos of the Arctic region. An intermediate incidence is observed in Southeast Asia (6-8). Therefore, the attempt at understanding how serum/plasma EBV DNA could be used for diagnosis and monitoring of NPC is crucial. In the present study, we applied nested PCR to analyze the incidence of serum/plasma EBV DNA during several phases of NPC, prior to as well as in the course of treatment and during follow-up. In addition, we determined whether the viral DNA was encapsulated. The data presented here not only demonstrate sensitivity and specificity of serum/plasma EBV DNA in each phase of the disease but also assist in an increasing comprehension as to its biological significance.

MATERIALS AND METHODS

Sample Collection. Upon informing the patients about the purpose of the study and obtaining their consent, primary NPC tissues were collected before onset of treatment at Chulalongkorn University Hospital. The tissues were divided into two parts. The first part was sent for routine histological examination. The second part was immediately stored in liquid nitrogen for future DNA extraction and PCR analysis for the presence of the EBV genome. All tumors were histologically ascertained to be undifferentiated NPC according to the WHO classification.

Blood samples were obtained by venipuncture from several groups of patients selected on the grounds that the EBV genome was present in their tumor tissues. The first group, 146 serum and 21 plasma samples, comprised patients prior to treatment. The second group included plasma samples obtained from 13

Received 10/21/99; revised 12/13/99; accepted 12/14/99.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by the Molecular Biology Project, Faculty of Medicine, Chulalongkorn University, and the Thailand Research Fund.

² The first two authors contributed equally to this work.

³ To whom requests for reprints should be addressed, at Genetics Unit, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. E-mail: mapiwat@chula.ac.th.

⁴ The abbreviations used are: NPC, nasopharyngeal cancer; EBNA, EBV nuclear antigen.

Fig. 1 Sensitivity of nested PCR for EBV DNA. A 100-bp ladder, distilled H₂O (*dH₂O*), and DNA from B958 cell lines were used as size standard, negative control, and positive control, respectively. A, compare sensitivity between single PCR and nested PCR for EBV DNA. B, examples of nested PCR for EBV DNA from NPC sera. Positive results were cases 45–48, 52, 53, 55–57, and 61. Most positive cases were EBV type A, whereas case 46 was EBV type B.




Table 1 Incidence of serum/plasma EBV DNA during various NPC management stages

Diagnosis	Status	Sample	Positive	Total (case)	%
NPC	Before treatment	Serum/plasma	98	167	58.7
		Serum	83	146	56.9
		Plasma	15	21	71.4
	Known positive EBV DNA in serum	Serum treated with DNAase	14	24	58.3
		Plasma (before Rx, 1, 2, 3–6 wks) ^a	(9, 6, 3, 1)	13	(69, 46, 23, 7)
		Plasma	3	37	8.1
	Recurrence or partial response	Plasma	3	5	60
		Plasma	0	32	0
	Complete remission	Serum	10	77	13.0

^a (before Rx, 1, 2, 3–6 wks) incidence of plasma EBV DNA before treatment at first, second, and third to sixth weeks during radiotherapy.

patients at the weekly complete blood count evaluation in the course of radiotherapy. The last group constituted 52 plasma samples from 37 patients, who after completion of treatment came to the hospital every 3 months for follow-up. The DNA samples extracted from the sera of healthy blood donors serving as controls in a previous study were used again for the same purpose (1). To obtain cell-free sera and plasma, clotted and EDTA blood specimens were centrifuged at low speed for 5 min within 1 h after venipuncture. Both sera and plasma samples were stored at -20°C until further analysis.

DNA Isolation and DNase Treatment. NPC tissue was incubated in Tris/HCl buffer containing SDS and proteinase K at 50°C overnight, followed by phenol/chloroform extraction and ethanol precipitation of DNA (9). As for serum or plasma, 200 μl were purified for DNA extraction on Qiaamp columns (Qiaamp blood kit; Qiagen, Basel Switzerland) according to the "blood and body fluid protocol." Ten sera and 10 plasma samples, respectively, were reanalyzed for the presence of the EBV genome to compare the efficiency of the Qiaamp blood kit with that of reextracting the nucleic acid with the QIAamp viral RNA

mini kit (Qiagen). One-tenth of the DNA extracted was then used for nested PCR analysis.

To distinguish free EBV DNA molecules from virions, 400 μl of 24 known positive EBV DNA serum samples were divided into two parts. The first part was twice digested extensively with DNase I (37°C for 1 h; Ref. 10). Both parts were then subjected to DNA extraction and nested EBV DNA PCR analysis. Semi-nested PCR for amplification of β -globin DNA was used to determine whether free DNA had been digested completely.

EBV Detection by Nested PCR. For the detection and typing of EBV DNA in tumor tissue and serum/plasma samples, nested PCR protocols were used, modifying those described previously for amplification of the EBNA-2 (11, 12). DNA extracted from the cell line B958, EBV-transformed lymphocytes (American Type Culture Collection), was used as positive control and double-distilled water as a negative control.

The first PCR amplified the EBNA-2, generating a DNA fragment of 237 bp for EBV type A and of 253 bp for EBV type B, respectively. With nested primers, the PCR product comprised 168 bp for EBV type A and 184 bp for EBV type B.




Fig. 2 Nested and seminested PCR from known EBV DNA-positive serum samples after DNase treatment. DNA. A 100-bp ladder, distilled H₂O (dH₂O), and DNA from B958 cell lines were used as size standard, negative control, and positive control, respectively. Lanes with (+) and without (-) DNase treatment are shown. A, seminested PCR for human β -globin. B, nested PCR for EBV DNA. All of these cases showed complete DNase treatment. Whereas cases 38 and 46 demonstrated resistant of EBV DNA from DNase, sera from cases 33, 47, and 48 were digested.

respectively. The nucleotide sequences for these first PCR primers were 5'-GCGGGTGGAGGGAAAGG-3' (E3-44mer) and 5'-GTCAGCCAAGGGACGCG-3' (E5-25mer). The nested PCR primers were E3 and E5 primers for EBNA2 (11, 12). Amplification of the β -globin gene by seminested PCR was used to determine the presence of amplifiable human DNA in all samples tested for EBV DNA. The primers GH20 and PCO4 were used for the first-round primary PCR, generating a DNA fragment of 260 bp (13). The β -globin-specific seminested primers were 5'-ACCTCACCCTGTGGAGCCA-3' (β -globin 62028) and PCO4, generating a 231-bp PCR product. The sequences of the primers used for EBNA-2 and β -globin PCRs were identical to those reported previously (11-13).

The first-round PCR reactions were performed in a total volume of 20 μ l using one-tenth of the extracted DNA in a reaction mixture containing 200 μ mol of each deoxynucleotide triphosphate, 1.5 mM magnesium chloride, 50 mM potassium chloride, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 0.5 unit of *Thermus aquaticus* DNA polymerase, and 0.2 μ M for EBV or 0.5 μ M for β -globin primers. The PCR amplification was performed as follows: initial denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 57°C for 30 s, with an extension at 72°C for 1 min, and a final extension at 72°C for 7 min. One μ l of each PCR product was used as the template for nested and seminested PCR, respectively. The 35 cycles of second-round PCR reactions were performed in a manner identical to that applied for the first-round PCR, except for using different sets of primers, 0.5 μ M for EBV or 1 μ M for β -globin primers, and adjusting the annealing temperature to 50°C. The PCR products were analyzed by electrophoresis on a 2% agarose gel stained with ethidium bromide upon preparation.

Statistical Analysis. Data regarding histology, tumor staging, EBV detection, and response to treatment were col-

lected in a double-blind fashion until analyzed. The χ^2 test was used to compare the results obtained from serum/plasma analysis with clinical and tumor parameters.

RESULTS

Sensitivity and Specificity of Nested PCR to Detect EBV DNA in Serum and Plasma. In this study, nested PCR was applied to improve the sensitivity for identifying EBV DNA. For the control cell line, nested PCR for EBNA-2 still yields a positive result with 10 fg DNA (Fig. 1). This suggests a much higher sensitivity of nested PCR. We then reevaluated sensitivity and specificity of EBV DNA detection in sera and plasma of NPC patients, as well as of normal blood donors (Table 1). Whereas higher sensitivity, 98 of 167 cases (58.68%), was demonstrated, fewer cases of normal blood donors, 10 of 77 cases (13%), showed positive results. The positive EBV DNA incidence from plasma samples, 71.4%, was slightly higher than from serum, 56.85%. Twenty previously analyzed samples, 10 serum and 10 plasma samples, were reextracted for nucleic acid by QIAamp viral RNA mini kit. With these samples, testing for the EBV genome was repeated by nested PCR and yielded identical results. There is no significant statistical correlation between serum EBV DNA and clinical parameters, staging, histological classification, or response to treatment at 3 and 6 months.

To evaluate whether the EBV DNA detected in serum was present as a free nucleic acid or within intact virions, 24 EBV DNA-positive sera from different patients were subjected to DNase I treatment prior to DNA extraction. After extensive DNase I treatment, nested PCR did not yield any detectable product of the control β -globin DNA, whereas nested PCR for EBV DNA remained positive for 14 cases (Fig. 2; Table 1).

Pt	PreRx	Radiotherapy (wk)						Post Rx 3-6 months	
		1	2	3	4	5	6		Pt status
P30	P	N	N	N	N	N	N	N	CR
365	P	N	N	N	N	N	N	N	CR
162	P	P	N	N	N	N	N	N	CR
P21	P	P	N	N	N	N	N	N	CR
P23	P	P	N	N	N	N	N	ND	CR
390	P	P	P	N	N	N	N	N	CR
406	P	P	P	N	N	N	N	ND	CR
374	P	P	P	P	P	P	P	ND	LF
363	N	N	N	N	N	N	N	N	CR
367	N	N	N	N	N	N	N	N	CR
P24	N	N	N	N	N	N	N	N	CR
P25	N	N	N	N	N	N	N	ND	CR
P27	N	N	N	N	N	N	N	N	CR

Fig. 3 Plasma EBV DNA at the end of each week during radiotherapy. Present (P) and absent (N) EBV DNA are shown prior (PreRx) and during treatment. NPC status of each patient at 3-6 months after treatment is demonstrated as complete remission (CR) and partial response (PR). LF, loss to follow up; ND, not done.

Plasma EBV DNA during Radiotherapy. Plasma samples were collected from 13 cases, and the EBV DNA status was determined on a weekly basis in the course of radiotherapy (Fig. 3; Table 1). Eight of these cases showed no serum/plasma EBV DNA prior to treatment and remained negative during treatment. In the others, serum/plasma EBV DNA was detectable prior to treatment. In seven of them, plasma EBV DNA disappeared within the first and third week of radiotherapy. One case showed persistence of plasma EBV DNA throughout the course of radiotherapy.

Sensitivity and Specificity of Plasma EBV DNA for Patients' Follow-Up. Fifty-two blood samples of 37 patients after treatment of between 3 and 42 months duration were evaluated at follow-up for the presence of the EBV genome in plasma (Fig. 4; Table 1). Using WHO criteria for response, five cases presented with evidence of NPC, three with recurrence, and two with partial response, $\geq 50\%$ decrease in total tumor size of the lesions and no appearance of new lesions or progression of any lesion. Plasma EBV DNA was detectable in three cases: one partial response, patient 365, and two recurrence cases, patients 72 and 106. Interestingly, whereas the plasma of both recurrence cases, patients 72 and 106, were positive for EBV DNA in their serum EBV DNA absent prior to treatment. Furthermore, repeated evaluation of the plasma for the EBV DNA status prior to further treatment twice in patient 106 and four times in patient 240, respectively, still showed identical results. The other 32 cases were in complete remission at the time of evaluation. Case 106R was patient 106 after the second course of radiotherapy. In the 32 plasma samples tested from all complete remission cases, some of which were examined more than once, no plasma EBV DNA was detectable. This suggested 100% specificity and 0% false positive rate, respectively, for serum/plasma EBV DNA to be used as an NPC tumor marker for follow-up after completion of treatment.

PT	Pre Rx	Post Rx (Month)																		Patient Status
		3	6	9	12	15	18	21	24	27	30	33	36	39	42					
72	CR																			CR
106	CR																			CR
139	CR																			CR
240	CR																			CR
365	CR																			CR
62	CR																			CR
66	CR																			CR
69	CR																			CR
106R	CR																			CR
148	CR																			CR
162	CR																			CR
170	CR																			CR
176	CR																			CR
177	CR																			CR
180	CR																			CR
203	CR																			CR
204	CR																			CR
209	CR																			CR
221	CR																			CR
249	CR																			CR
262	CR																			CR
269	CR																			CR
267	CR																			CR
272	CR																			CR
278	CR																			CR
297	CR																			CR
306	CR																			CR
328	CR																			CR
363	CR																			CR
367	CR																			CR
385	CR																			CR
390	CR																			CR
398	CR																			CR
P21	CR																			CR
P24	CR																			CR
P27	CR																			CR
P30	CR																			CR

Fig. 4 Serum/plasma EBV DNA during follow-up after complete treatment. NPC status of each patient is demonstrated as recurrence (R), partial response (PR), and complete remission (CR). Present (P) and absent (N) of EBV DNA are shown. ND, not done.

DISCUSSION

The discovery of tumor-derived DNA in the circulation of cancer patients implies the possibility of a new strategy for noninvasive cancer detection and monitoring (1-3). For NPC, using EBV DNA for this purpose should prove advantageous because virtually all cases of NPC have been found associated with EBV (14, 15). Because a comparison between two studies has shown much divergence as to the prevalence of EBV DNA in serum/plasma samples, we improved the sensitivity for further analysis by using nested PCR (4, 5). This technique should prove to be the one with the highest sensitivity. Several positive cases (13%) were identified among normal blood donors infected previously with EBV, compared with not a single case identified previously by one-round PCR or with 7% established by the quantitative PCR study. The present study revealed serum/plasma EBV DNA to be present in 58.68% of NPC cases. Although plasma samples demonstrated a slightly higher prevalence of EBV DNA, there was no significant difference of DNA identification between plasma and serum samples or between two different DNA extraction methods, Qiaamp blood kit and Qiaamp viral RNA mini kit. The continuous presence or absence of EBV DNA in serum/plasma was confirmed by repeatedly evaluating the plasma for EBV DNA status in two patients. The difference in prevalence of the tumor DNA in the circulation of NPC patients was similar to that reported for other types of cancer. For example, the frequency of identifying serum/plasma colorectal cancer DNA can vary between studies

from 40 to 90% (16–18). Although differences in serum/plasma EBV DNA between EBV DNA prevalence reported by real time PCR and nested PCR may be attributable to different PCR primers and detection system. Nevertheless, as yet unsuspected biochemical and/or environmental mechanisms may be responsible for this finding.

Serum/plasma EBV DNA has been studied in several conditions, such as infectious mononucleosis, acute lymphoproliferative disorder, and EBV-associated lymphoma (19–24). In addition to the association with EBV-associated cancers, serum/plasma EBV DNA was found to be an indicator for active infection rather than latent virus (19, 21–24). The purpose of the DNase digestion experiment was to establish whether the presence of serum EBV DNA was attributable to lytic replication or release of latent episomal DNA. The results suggest that there might be two simultaneously present populations of serum EBV DNA, one encapsulated in the viral particle and the other the free nucleic acid probably released from NPC as episomal DNA. The presence of virions in the circulation of NPC patients is surprising because the majority of EBV in NPC cells should be in the latent phase, as shown by EBV clonal studies (25, 26). Consequently, serum/plasma EBV DNA should all be present as free nucleic acids. Nevertheless, our data invite the hypothesis that some EBV in NPC should enter lytic replication. This could explain why antibody titers to lytic cycle antigens, such as VCA and ZEBRA, rise in NPC patients (27, 28). In addition, expression of the immediate early *BZLF1* and *BHLF1* genes or ZEBRA protein is frequently detectable in NPC (29, 30). Because there may be only few cells entering lytic viral replication, studying the clonal progression of EBV by analyzing terminal repeat lengths by Southern blot and hybridization may not be sensitive enough to commonly detect the lytic replication or might be interpreted as impurities and hence ignored. Definite proof, such as electron microscopic analysis, is required to identify virions in NPC circulation.

Studying plasma EBV DNA during radiotherapy not only suggests a direction to further explore the behavior of EBV DNA present in the circulation of patients receiving radiotherapy but may also lead to clinical implications. EBV DNA positive in serum/plasma before treatment disappeared early in the course of radiotherapy, whereas plasma EBV DNA initially negative remained negative. This suggests two important findings: (a) serum/plasma EBV DNA is short lived; and (b) cell death as a consequence of radiation does not promote the presence of EBV DNA in the patients' circulation. On the contrary, because EBV DNA could disappear from plasma as early as during the first week of treatment, radiation may in addition to its ability to decrease the number of NPC cells use a specific mechanism that prevents the tumor from releasing EBV DNA. The biological effect of ionizing radiation at the cellular and molecular level appears to be DNA double strand break and a subsequent activation of DNA-dependent protein kinase (31, 32). It will be interesting to further explore whether DNA-dependent protein kinase plays any role in the release of EBV DNA from NPC into the patients' circulation. Whereas most cases of previously positive serum/plasma EBV DNA disappeared during radiation, one case showed persistence of plasma EBV DNA. This NPC case may not respond to the radiation induced inhibition of virus release, or it may indicate microme-

tastases. This persistence of serum/plasma EBV DNA during radiotherapy may be crucial for future clinical treatment modalities.

The other important clinical application of serum/plasma EBV DNA with NPC suggested here is as a tumor marker for patients' follow-up. NPC is a form of cancer with a high success rate of radiochemotherapy (33). However, many cases may recur, even after very long periods of latency (34). Consequently, most NPC patients require very consistent and long follow-up studies. Some of them may require expensive investigations, such as computed tomography scan or invasive methods, especially punch biopsy. Analyzing serum/plasma EBV DNA is an inexpensive and noninvasive technique suitable for clinical application. Upon using plasma EBV DNA as a marker for follow-up, the sensitivity (60%) shown in this study was similar to the prevalence detected prior to treatment. In addition, whereas only patients with evidence of disease showed plasma EBV DNA, the DNA was not detectable in any of the cases with complete remission. This suggested 100% specificity and a 0% rate of false positives. Interestingly, whereas we detected 13% of serum EBV DNA in 77 healthy individuals, no EBV DNA was identified in 42 tests of 32 NPC cases with complete remission. The usefulness of serum/plasma EBV DNA as a molecular marker for NPC patient monitoring was emphasized recently by Lo *et al.* (35). They demonstrated a close relationship between plasma/serum EBV DNA quantity and tumor recurrence. In addition, significant elevations in serum EBV DNA were observed in the patients who subsequently developed tumor recurrence.

In conclusion, this study has shown how frequently serum/plasma EBV DNA can be discovered in the course of NPC prior, during, and after treatment. Approximately 59% of NPCs prior to treatment were positive for serum/plasma EBV DNA. The presence and/or absence of serum/plasma EBV DNA is likely to depend on each individual and remain persistent as long as there is no change in the tumor status. Radiotherapy cannot induce but rather prevents NPC from releasing EBV DNA into the patients' circulation. Finally, investigating serum/plasma EBV DNA after treatment suggested its potential as a tumor marker.

ACKNOWLEDGMENTS

We are deeply indebted to the staff of the Department of Otolaryngology and the Radiotherapy Section, Department of Radiology, Chulalongkorn University Hospital and National Blood Center for the recruitment of patients and collection of materials. We also thank Petra Hirsch for critical review of the manuscript.

REFERENCES

1. Nawroz, H., Koch, W., Anker, P., Stroun, M., and Sidransky, D. Microsatellite alterations in serum DNA of head and neck cancer patients. *Nat. Med.*, 2: 1035–1037, 1996.
2. Chen, X. Q., Stroun, M., Magnenat, J. L., Nicod, L. P., Kurt, A. M., Lyautey, J., Lederrey, C., and Anker, P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. *Nat. Med.*, 2: 1033–1035, 1996.
3. Anker, P., Mulcahy, H., Chen, X. Q., and Stroun, M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. *Cancer Metastasis Rev.*, 18: 65–73, 1999.
4. Mutirangura, A., Pornthanakasem, W., Theamboonlers, A., Sriuranpong, V., Lertsanguansinchi, P., Yenrudi, S., Voravud, N., Supiyaphun,

- P., and Poovorawan, Y. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. *Clin. Cancer Res.*, 4: 665-669, 1998.
5. Lo, Y. M. D., Chan, L. Y. S., Lo, K. W., Leung, S. F., Zhang, J., Chan, A. T. C., Lee, J. C. K., Hjelm, N. M., Johnson, P. J., and Huang, D. P. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. *Cancer Res.*, 59: 1188-1191, 1999.
6. Vokes, E. E., Liebowitz, D. N., and Weichselbaum, R. R. Nasopharyngeal carcinoma. *Lancet*, 350: 1087-1091, 1997.
7. Sasco, A. J. Screening for nasopharyngeal carcinoma. *B. Cancer*, 83: 344-351, 1996.
8. Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., and Hong, W. K. Head and neck cancer. *N. Engl. J. Med.*, 328: 184-194, 1993.
9. Maniatis, T., Fritsch, E. F., and Sambrook, J. *Molecular Cloning: A Laboratory Manual*, Ed. 2, pp. 9.16-9.23. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
10. Cabrerizo, M., Bartolome, J., DeSequera, P., Caramelo, C., and Carreno, V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. *J. Am. Soc. Nephrol.*, 8: 1443-1447, 1997.
11. Sample, J., Young, L., Martin, B., Chatman, T., Kieff, E., Rickinson, A., and Kieff, E. Epstein-Barr virus types 1 and 2 differ in their *EBNA-3A*, *EBNA-3B*, and *EBNA-3C* genes. *J. Virol.*, 64: 4084-4092, 1990.
12. Lin, J. C., Lin, S. C., De, B. K., Chan, W. C., and Evatt, B. L. Precision of genotyping of Epstein-Barr virus by polymerase chain reaction using three gene loci (*EBNA-2*, *EBNA-3C*, and *EBER*): predominance of type A virus associated with Hodgkin's disease. *Blood*, 81: 3372-3381, 1993.
13. Resnick, R. M., Cornelissen, M. T., Wright, D. K., Eichinger, G. H., Fox, H. S., ter Schegget, J., and Manos, M. M. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. *J. Natl. Cancer Inst.*, 82: 1477-1484, 1990.
14. Vasef, M. A., Ferlito, A., and Weiss, L. M. Nasopharyngeal carcinoma with emphasis on its relationship to Epstein-Barr virus. *Ann. Otol. Rhinol. Laryngol.*, 106: 348-356, 1997.
15. Chen, C. L., Wen, W. N., Chen, J. Y., Hsu, M. M., and Hsu, H. C. Detection of Epstein-Barr virus genome in nasopharyngeal carcinoma by *in situ* DNA hybridization. *Intervirology*, 36: 91-98, 1993.
16. Hibi, K., Robinson, C. R., Booker, S., Wu, L., Hamilton, S. R., Sidransky, D., and Jen, J. Molecular detection of genetic alterations in the serum of colorectal cancer patients. *Cancer Res.*, 58: 1405-1407, 1998.
17. Kopreski, M. S., Benko, F. A., Kwee, C., Leitzel, K. E., Eskander, E., Lipton, A., and Gocke, C. D. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. *Br. J. Cancer*, 76: 1293-1299, 1997.
18. DeKok, J. B., Van Solinge, W. W., Ruers, T. J. M., Roelofs, R. W. H. M., VanMuijen, G. N. P., Willems, J. L., and Swinkels, D. W. Detection of tumour DNA in serum of colorectal cancer patients. *Scand. J. Clin. Lab. Investig.*, 57: 601-604, 1997.
19. Yamamoto, M., Kimura, H., Hironaka, T., Hirai, K., Hasegawa, S., Kuzushima, K., Shibata, M., and Morishima, T. Detection and quantification of virus DNA in plasma of patients with Epstein-Barr virus-associated diseases. *J. Clin. Microbiol.*, 33: 1765-1768, 1995.
20. Gallagher, A., Armstrong, A. A., MacKenzie, J., Shield, L., Khan, G., Lake, A., Proctor, S., Taylor, P., Clements, G. B., and Jarrett, R. F. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. *Int. J. Cancer*, 84: 442-448, 1999.
21. Fontan, J., Bassignot, A., Mougin, C., and Cahn, J. Y. Detection of Epstein-Barr virus DNA in serum of transplanted patients: a new diagnostic guide for lymphoproliferative diseases. *Leukemia*, 12: 772, 1998.
22. Gan, Y. J., Sullivan, J. L., and Sixbey, J. W. Detection of cell-free Epstein-Barr virus DNA in serum during acute infectious mononucleosis. *J. Infect. Dis.*, 170: 436-439, 1994.
23. Mouritsen, C. L., Wittwer, C. T., Reed, G., Khan, T. M., Martins, T. B., Jaskowski, T. D., Litwin, C. M., and Hill, H. R. Detection of Epstein-Barr viral DNA in serum using rapid-cycle PCR. *Biochem. Mol. Med.*, 60: 161-168, 1997.
24. Limaye, A. P., Huang, M. L., Atienza, E. E., Ferrenberg, J. M., and Corey, L. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. *J. Clin. Microbiol.*, 37: 1113-1116, 1999.
25. Lin, C. T., Chen, W., Hsu, M. M., and Dee, A. N. Clonal versus polyclonal Epstein-Barr virus infection in nasopharyngeal carcinoma cell lines. *Lab. Investig.*, 76: 793-798, 1997.
26. Pathmanathan, R., Prasad, U., Sadler, R., Flynn, K., and Raab, Traub, N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. *N. Engl. J. Med.*, 333: 693-698, 1995.
27. Joab, I., Nicolas, J. C., Schwaab, G., de The, G., Clausse, B., Perricaudet, M., and Zeng, Y. Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. *Int. J. Cancer*, 48: 647-649, 1991.
28. Zeng, Y., Zhang, L. G., Li, H. Y., Jan, M. G., Zhang, Q., Wu, Y. C., Wang, Y. S., and Su, G. R. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. *Int. J. Cancer*, 29: 139-141, 1982.
29. Cochet, C., Martel-Renoir, D., Grunewald, V., Bosq, J., Cochet, G., Schwaab, G., Bernaudin, J. F., and Joab, I. Expression of the Epstein-Barr virus immediate early gene, *BZLF1*, in nasopharyngeal carcinoma tumor cells. *Virology*, 197: 358-365, 1993.
30. Martel-Renoir, D., Grunewald, V., Touitou, R., Schwaab, G., and Joab, I. Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. *J. Gen. Virol.*, 76: 1401-1408, 1995.
31. Hall, E. J. Molecular biology in radiation therapy: the potential impact of recombinant technology on clinical practice. *Int. J. Radiat. Oncol. Biol. Phys.*, 30: 1019-1028, 1994.
32. Jin, S., Inoue, S., and Weaver, D. T. Functions of the DNA dependent protein kinase. *Cancer Surv.*, 29: 221-261, 1997.
33. Kraiphibul, P., and Atichartakarn, V. Treatment of nasopharyngeal carcinoma. *J. Med. Assoc. Thai.*, 75: 435-444, 1992.
34. Lee, A. W. M., Foo, W., Law, S. C. K., Poon, Y. F., Sze, W. M., Tung, S. Y., Chappell, R., Lau, W. H., and Ho, J. H. C. Recurrent nasopharyngeal carcinoma: the puzzles of long latency. *Int. J. Radiat. Oncol. Biol. Phys.*, 44: 149-156, 1999.
35. Lo, Y. M. D., Chan, L. Y. S., Chan, A. T. C., Leung, S. F., Lo, K. W., Zhang, J., Lee, J. C. K., Hjelm, N. M., Johnson, P. J., and Huang, D. P. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. *Cancer Res.*, 59: 5452-5455, 1999.

Genetic heterogeneity and progression in different areas within high-grade diffuse astrocytoma

SHANOP SHUANGSHOTI¹, YOT NAVALITLOHA², VIRA KASANTIKUL¹,
SAMRUAY SHUANGSHOTI¹ and APIWAT MUTIRANGURA³

Departments of ¹Pathology, ²Surgery and ³Genetics Unit, Department of Anatomy,
Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Received July 29, 1999; Accepted October 18, 1999

Abstract. The primary objective of this study was to determine loss of heterozygosity (LOH) in various portions of 9 high-grade diffuse astrocytomas, 8 glioblastomas and 1 anaplastic astrocytoma. LOH was observed on chromosomes 9, 10, 17 and 19 in 8, 3, 4 and 2 cases, respectively. Genetic heterogeneity and a multistep process were identified in 4 glioblastomas explaining the diverse morphological characteristics, a common feature of diffuse astrocytomas. In 2, 2, 3 and 1 cases, the allele losses were found within part of grade IV astrocytomas but not grades II or II/III, on chromosomes 9, 10, 17 and 19, respectively. In one of these, while genetic heterogeneity was observed on chromosome 17 between the area of grade II and grade IV, 9pLOH was found within both areas and occurred on the same allele. The other 5 cases did not demonstrate genetic heterogeneity and the LOH was on the same allele, irrespective of grade, suggesting clonal origin. In conclusion, at the molecular level, the diverse morphological features of astrocytoma develops by a multistep mechanism of genetic alterations from one cell via low-grade and more malignant tumors towards glioblastoma.

Introduction

Diffuse astrocytoma is the most commonly occurring intracranial tumors, accounting for more than 60% of all neoplasms of the brain (1). Various evidence suggested the development of this cancer to proceed by a multistep process (2-4). Some of the most malignant forms, glioblastoma, arises secondarily

from a number of lower grade gliomas. Secondly, some genetic alterations, such as loss of heterozygosity on chromosomes 9p, 10q and 19q, are found more frequently in anaplastic astrocytoma and glioblastoma, but are rare in low-grade astrocytoma (2-5). Finally, based on morphological criteria, heterogeneity is frequently found in this cancer. It should be noted that within a high-grade tumor, areas displaying low-grade tumor growth can be found (1,6,7). In addition heterogeneity has been observed with respect to the expression of tumor antigens (8), cell proliferation kinetics (9), cytogenetics (10) and telomerase activity (11).

Diffuse astrocytoma arises after multiple genetic aberrations. Molecular genetic studies implicate several oncogenes and tumor suppressor genes to be involved as for example, *TP53*, *EGFR*, *CDK4*, *MDM2*, *CDKN2A* and *PTEN* (12-17). Loss of heterozygosity was also found on a number of chromosomes, 9p, 10q, 13q, 17p and 19q to date (18). Interestingly, not every glioblastoma shows all the genetic changes described suggesting several independent pathways leading to the common end point (18). Hence, the morphological heterogeneity observed would be a result of the multistep carcinogenesis. Genetic distinction between lower- and higher-grade stages of the same tumor would provide more insight into astrocytoma development. Contrasting this hypothesis, a study on genetic heterogeneity in 1992 demonstrated all genetic changes analysed in 4 cases to be identical between low-grade and high-grade tumors (19). We propose to re-evaluate the genetic abnormalities characteristic for high-grade diffuse astrocytomas in areas of different gradation as to whether there is genetic heterogeneity in the individual tumor which could explain the genetic pathway of astrocytoma development.

Correspondence to: Dr Apiwat Mutirangura, Genetics Unit, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Abbreviations: WHO, World Health Organization; LOH, loss of heterozygosity; MSI, microsatellite instability

Key words: loss of heterozygosity, astrocytoma, genetic heterogeneity, multistep process, glioblastoma

Materials and methods

Tissues and DNA extraction. Nine large diffuse astrocytoma with distinct areas of different gradation, according to guidelines of the WHO (World Health Organization), were obtained from paraffin-embedded specimens (20). These comprised 8 glioblastomas (astrocytoma grade IV) with lower-grade astrocytoma areas (grade II and grade II/III in 4 cases each) and 1 anaplastic astrocytoma (grade III) containing grade-II portion. Grade II/III areas represented a distinct

Table I. Loss of heterozygosity in different areas of 9 astrocytomas.

Case		1			2			3			4			5			6			7			8			9		
Chro	STR	N	II	III	N	II	IV	N	II	IV	N	II	IV	N	II	IV	N	II/III	IV	N	II/III	IV	N	II/III	IV	N	II/III	IV
9	D9S1748		U		2	2	1		U		U		2	2	2		U		2	2	1	2	1	1		U		
	RPS6		U		2	2	1		U		2	1	1	2	1	1	2	1	1	2	2	1		U		2	2	2
	IFNA	2	1	1	2	0	1	2	1	1	2	1	1	2	1	1		U		U			U		2	2	2	
10	D10S196	2	2	2		U		2	2	2	2	2	2		U		2	1	1		U			U		2	2	1
	D10S249	2	2	2	0	1	1	0	0	2	0	1	1		U		2	1	1	2	2	2	2	1	1	2	0	1
	D10S187	2	2	2	2	2	2		U		2	2	2		U		2	2	2	2	2	1		U		2	2	2
17	D17S1176		U		2	2	2	2	2	2	0	2	2	2	2	1	2	2	2	2	2	1	1	M	M	2	2	M
	TP53	2	1	1		U		2	2	2	0	1	1	2	2	1	2	2	2	2	2	2	M	2	2	2	2	1
19	D19S47	2	2	2		U		U		2	2	2		U		2	2	2	2	2	2	2	2	2	2	2	2	2
	ERCCI		U		2	2	1	2	1	1	2	2	2	2	0	2	2	0	2	2	2	2		U			U	

Chro, chromosome; STR, microsatellite; N, normal; II, astrocytoma WHO grade II; II/III, astrocytoma WHO grade II/III; IV, astrocytoma WHO grade IV (glioblastoma); 2, heterozygosity; 1, one allele detected; 0, could not be amplified; M, microsatellite instability; U, uninformative.

region in 4 glioblastomas consisting of low to moderate cellularity of well differentiated tumor cells retaining the astrocytic appearances but began to show a few mitotic figures. Fifteen to twenty 4 μ m sections per sample were stained with hematoxylin and eosin and left uncovered. Under an inverted light microscope, the differently graded areas in each tumor were microdissected for molecular analysis using 27-30 gauge steel needles (21). In this context, the term 'high-grade diffuse astrocytoma' means either anaplastic astrocytoma or glioblastoma.

Blood samples collected by venipuncture served as constitutional controls in cases 1, 5, 6 and 7. Since all tumor samples included in our study were large and contained normal tissue such as neurons in the cerebral cortex, these normal cells were microdissected and used as internal controls. DNA was extracted from paraffin-embedded tissue and circulating leukocytes as described elsewhere (21).

Allelotyping. Ten microsatellite markers on chromosomes 9p, 10q, 17p and 19q used for PCR analyses are listed in Table I. Information regarding cytogenetic localization of the markers was provided by the Genome Data Base.

Prior to microsatellite analyses, DNA extracted from paraffin-embedded tissue was amplified by DOP-PCR in a total volume of 50 μ l as previously described (22,23). One strand of each primer pair was end-labeled as described elsewhere (24). The PCR reactions were performed in a total reaction volume of 10 μ l comprising 200 μ M dNTP each, 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl₂, 0.5 units of *Thermus aquaticus* DNA polymerase (Amersham Pharmacia Biotech, Little Chalfont, UK), primer concentrations between 0.05-0.1 μ M each, and 50 ng of genomic DNA obtained from both leukocyte extraction and DOP-PCR of extracted paraffin-embedded specimens.

Several PCR reactions have been optimized for each primer set as follows: an initial denaturation step at 95°C for 4 min, followed by 40 cycles of denaturation at 94°C for 1 min, with 1 min annealing at 55°C, extension at 72°C for 2 min and a final extension at 72°C for 7 min.

Aliquots (2 μ l) of each reaction were mixed with 1 μ l formamide-loading buffer, heated at 95°C for 2 min, chilled on ice for 30 sec, then loaded onto a 6% polyacrylamide 7 M urea gel. DNA fragments were size fractionated at 70 W until the tracking dye had covered the appropriate distance on the gel. After electrophoresis, the wet gel was transferred to filter paper (Whatman, Maidstone, UK), covered with Saran wrap and exposed to a phosphorus screen and the bands were visualized on a PhosphorImager using ImageQuaNT™ software (Molecular Dynamics, Sunnyvale, CA).

Results

Table I shows microsatellite alterations observed in 9 high grade diffuse astrocytomas. Allelic losses were scored when at least one microsatellite locus on each chromosome examined was informative and revealed loss of one allele in comparison with matched normal DNA. Genetic heterogeneity was recorded when areas within the same tumor exhibiting the lowest and the highest gradation were genetically different. Microsatellite instability (MSI) as reflected by variations in length of microsatellite repeats in tumor DNA was also recorded. On the example of case 5, representative histopathology with corresponding loss of heterozygosity (LOH) is shown in Figs. 1 and 2.

Frequencies of LOH corresponding to the highest histopathological grade of each tumor were found in 8/9 (89%) of chromosome 9p, 4/8 (50%) of chromosomes 10q and 17p, and 2/9 (22%) of chromosome 19q, respectively. The




Figure 1. Histopathology of astrocytoma grade IV (glioblastoma) from case no. 5. A, Low magnification reveals grade II astrocytoma area consisting of neoplastic astrocytes with nuclear atypia. B-D, Medium and high magnifications display astrocytoma grade IV area as evidenced by marked nuclear pleomorphism with mitosis (B), vascular proliferation (C), and pseudopalisading necrosis (D).



Figure 2. Microsatellite analysis in selected diffuse astrocytomas, case 5, showing genetic heterogeneity of chromosome 17, D17S1176, but not chromosome 9, IFNA. Representative astrocytoma grade II, IV and corresponding normal tissue (N) are shown with microsatellite markers.

areas with the lowest gradation in each sample exhibited a lesser incidence of LOH, that is, 6/9 (67%) on chromosome 9p, 2/8 (25%) on chromosome 10q, and 1/8 (12%) on both chromosomes 17p and 19q. In case of LOH present in both the lower- and higher-grade areas, the loss had originated from the same allele.

Genetic heterogeneity could be identified in 4 tumors (44%), that is, in cases no. 2 (chromosomes 9p and 19q), no. 5 (chromosome 17p), no. 7 (chromosomes 9p, 10q, and 17p), and no. 9 (chromosomes 10q and 17p). In case no. 5, whereas chromosome 17p showed genetic heterogeneity, chromosome 9p originating from either a grade II or grade IV area demonstrated identical genetic components (Fig. 2). The remaining samples displayed no genetic differences.

MSI was observed in 3 tumors, more specifically, in grade IV areas of cases nos. 7 and 9, and both grade II/III and IV portions of case no. 8.

Discussion

High-grade diffuse astrocytomas, like other malignant neoplasms, are histopathologically heterogeneous tumors (6,7). This phenomenon might be explained by the tumor evolution hypothesis that all neoplastic cells are derived from the same clonal origin but differ by stages of genetic alterations, resulting in diverse morphological appearance of tumor cells within the same lesion. However, a previous study has not been able to demonstrate such genetic heterogeneity on chromosomes 9p, 10, and 17p in 2 glioblastomas and 2 anaplastic astrocytomas, regions presumed to be related to tumor progression in diffuse astrocytoma (19). In our study, additional application of microdissection technique, as well as an increased number of analyzed glioblastomas and chromosomes have established the existence of genetic heterogeneity as evidenced by retention of both alleles in the grade-II or grade-II/III areas and LOH in the glioblastomatous area of the same tumor. The varying genetic alterations correspond well to the histopathological gradation. Our findings strongly support abnormal genetic events to increasingly occur during the multistep process of glioblastoma development.

The detection of LOH in grade II or grade II/III areas on chromosome 9p (cases nos. 1, 3-6, and 8), chromosome 10q (cases nos. 6 and 8), and chromosome 19q (case no. 3) was of interest since LOH in these regions has been unequivocally associated with malignant progression of diffuse

astrocytomas. Their frequencies of allelic loss are directly proportional to an increase in histopathological severity (2-5). Furthermore, chromosomes 9p21 and 10q23.3, respectively, harbor the candidate tumor suppressor genes *CDKN2A* and *PTEN*, both genes also play a role in malignant transformation of astrocytomas (5,18). LOH detected at the 3 chromosome loci in the low grade area implies that some genetic alterations in diffuse astrocytoma have already occurred before morphological changes could be discerned by conventional methods. These molecular markers may be employed as additional criteria or unfavorable prognostic indicators in cases of diffuse astrocytoma where histological features alone are insufficient to diagnose grade III or grade IV tumors. However, large series of well-controlled trials are required in order to fully evaluate the applicability of this molecular tool.

The *TP53* gene located on the short arm of chromosome 17 is involved not only in the initiation but also in the progression of gliomas (25,26). Apparently, in case no. 1 the former role has been favored as LOH 17p could be demonstrated in both grade II and grade II/III portions. Contrasting that, LOH 17p appeared to be a late event in the malignant progression from grade II and III astrocytomas toward glioblastomas in cases nos. 5, 7, and 9 as evidenced by the presence of LOH only in the grade IV area. Hence, our data differ from all three molecular subtypes of glioblastomas recently proposed (18). However, we suggest that all glioblastomas included in our study belong to the 'secondary' form as defined by Scherer (27) as each one contained a distinct area of lower grade lesion. There might be other, as yet undiscovered genetic pathways responsible for the development of glioblastomas.

MSI, a result of replication errors, has been suggested as a possible mechanism in the initiation of cancer. Since the frequency of MSI has been reported between 30-50% in glioblastomas but is very rare in low grade diffuse astrocytomas, this phenomenon is considered an evolution in astrocytoma progression rather than the initial event (28,29). The occurrence of MSI in 3 cases of grade IV tumor opposed to none of the grade II portions supports these previous observations.

To summarize, our current study has demonstrated genetic heterogeneity to be discernible in diffuse astrocytoma which provides an explanation for the variety in morphological appearance of neoplastic astrocytes within the same lesion. In addition, some genetic alterations already exist in morphologically low-grade areas of a high-grade tumor. These antecedent molecular changes may be utilized as additional molecular diagnostic criteria or prognostic markers. Finally, the microdissection technique may unravel the complex molecular pathways employed in tumorigenesis and malignant progression of diffuse astrocytomas.

Acknowledgements

We would like to express our gratitude to the staff of the Department of Pathology, Chulalongkorn University, who provided all clinical samples; to Ms. Sairoonee and Mr. Wichai Porntanakasem for technical assistance and to Ms. Petra Hirsch for critical review of the manuscript. This work was supported by the Molecular Biology Project,

Faculty of Medicine, Chulalongkorn University, and the Thailand Research Fund.

References

1. Lantos PL, Vandenberg SR and Kleihues P: Tumors of the nervous system. In: Greenfield's Neuropathology. 6th edition. Graham DI and Lantos PL (eds). Arnold, London, pp606-627. 1997.
2. Fuhs D, Brockmeyer D, Tullous MW, Pedone CA and Cawthon RM: P53 mutation and loss of heterozygosity on chromosome 17 and 19 during human astrocytoma progression. *Cancer Res* 52: 674-679, 1992.
3. Von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD and Seizinger BR: Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. *Cancer Res* 52: 4277-4279, 1992.
4. Lang FF, Miller DC, Koslow M and Newcomb EW: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. *J Neurosurg* 81: 427-436, 1994.
5. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF and Tavtigian SV: Identification of a candidate tumor suppressor gene, *MMAC1*, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nat Genet* 15: 356-362, 1997.
6. Paulus W and Peiffer J: Intratumoral histologic heterogeneity of gliomas. *Cancer* 64: 442-447, 1989.
7. Burger PC and Kleihues P: Cytologic composition of the untreated glioblastoma with implication for evaluation of needle biopsies. *Cancer* 64: 2014-2023, 1989.
8. Bilzer T, Martin B, Stavrou D and Keiditsch E: Simultaneous demonstration of glia- and glioma-associated antigens in human astrocytomas. *Int J Cancer* 2: 41-44, 1988.
9. Perez LA, Dombkowski D, Efrid J, Pfeffer F and Suit HD: Cell proliferation kinetics in human tumor xenografts measured with iododeoxyuridine labeling and flow cytometry: a study of heterogeneity and a comparison between different methods of calculation and other proliferation measurements. *Cancer Res* 55: 392-398, 1995.
10. Coons SW, Johnson PC and Shapiro JR: Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in low grade human glioma. *Cancer Res* 55: 1569-1577, 1995.
11. Kleinschmidt-deMasters BK, Hashizumi TL, Sze C-I, Lillehei KO, Shroyer AL and Shroyer KR: Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling. *J Clin Pathol* 51: 284-293, 1998.
12. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD and Bigner SH: Alterations of the *TP53* gene in human gliomas. *Cancer Res* 54: 1324-1330, 1994.
13. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N and Kiessling M: Amplification of the epidermal-growth-factor-receptor gene correlates with different growth-behavior in human glioblastoma. *Int J Cancer* 56: 72-77, 1994.
14. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS and James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. *Cancer Res* 54: 5804-5807, 1994.
15. Kondo S, Kondo Y, Hara H, Kaakaji R, Peterson JW, Morimura T, Takeuchi J and Barnett GH: mdm2 gene mediates the expression of mdm1 gene and P-glycoprotein in a human glioblastoma cell line. *Br J Cancer* 74: 1263-1268, 1996.
16. Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WK and Kyritsis AP: Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. *Oncogene* 13: 1615-1619, 1996.
17. Somerville RP, Shoshan Y, Eng C, Barnett G, Miller D and Cowell JK: Molecular analysis of two putative tumour suppressor genes, *PTEN* and *DMBT*, which have been implicated in glioblastoma multiforme disease progression. *Oncogene* 17: 1755-1757, 1998.
18. Von Deimling A: Differential patterns of molecular genetic alterations define subsets among glioblastomas and oligoastrocytomas. *Neuropathology* 18: 145-153, 1998.

9. Leenstra S, Troost D, Westerveld A, Bosch DA and Hulsebos TJM: Molecular characterization of areas with low grade tumor or satellitosis in human malignant astrocytomas. *Cancer Res* 52: 1568-1572, 1992.
10. Kleihues P, Burger PC and Scheithauer BW (eds): *Histological Typing of Tumors of the Central Nervous System*. 2nd edition. Springer-Verlag, Berlin, 1993.
11. Moskaluk CA and Kern SE: Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. *Am J Pathol* 5: 1547-1552, 1997.
12. Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA and Tunnacliffe A: Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. *Genomics* 3: 718-725, 1992.
13. Mutirangura A, Charuruks N, Shuangshoti S, Sakdikul S, Chatsantikul R, Pornthanakasem W, Sriuranpong V, Supiyaphun P and Voravud N: Identification of distinct regions of allelic loss on chromosome 13q in nasopharyngeal cancer from paraffin embedded tissues. *Int J Cancer* 83: 210-214, 1999.
24. Mutirangura A, Tanunyutthawongse C, Pornthanakasem W, Kerekhanjanarong V, Sriuranpong V, Yenrudi S, Supiyaphun P and Voravud N: Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. *Br J Cancer* 6: 770-776, 1997.
25. Van de Kelft E: Molecular pathogenesis of astrocytoma and glioblastoma multiforme. *Acta Neurochir* 139: 589-599, 1997.
26. Sidransky D, Mikkelsen T, Schwechheimer, Rosenblum ML, Cavanee W and Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. *Nature* 355: 846-847, 1992.
27. Scherer HJ: Cerebral astrocytomas and their derivatives. *Am J Cancer* 40: 159-198, 1940.
28. Van de Kelft E and Verlooy J: Instability of short tandem repeats (microsatellites) I human gliomas. *J Neurosurg Sci* 38: 203-208, 1994.
29. Dams E, van de Kelft E, Martin J-J, Verlooy J and Willems PJ: Instability of microsatellites in human gliomas. *Cancer Res* 55: 1547-1549, 1995.

Research article

Human papillomavirus DNA in plasma of patients with cervical cancer**Wichai Pornthanakasem¹, Kanjana Shotelersuk², Wichai Termrungruanglert³, Narin Voravud⁴, Somchai Niruthisard³ and Apiwat Mutirangura^{*5}**

Address: ¹Department of Microbiology,, ²Department of Radiology, Division of Radiation Oncology,, ³Department of Obstetrics and Gynecology,, ⁴Department of Medicine, Medical Oncology Unit, and ⁵Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

E-mail: Wichai Pornthanakasem - pornthanakasem_w@hotmail.com; Kanjana Shotelersuk - fmedvst@md2.md.chula.ac.th; Wichai Termrungruanglert - fmed@md2.md.chula.ac.th; Narin Voravud - eu_medonco@hotmail.com; Somchai Niruthisard - fmedsnr@md2.md.chula.ac.th; Apiwat Mutirangura* - mapiwat@chula.ac.th

*Corresponding author

Published: 5 March 2001

Received: 31 January 2001

BMC Cancer 2001, 1:2

Accepted: 5 March 2001

This article is available from: <http://www.biomedcentral.com/1471-2407/1/2>

(c) 2001 Pornthanakasem et al. licensee BioMed Central Ltd

Abstract

Background: Human papillomavirus (HPV) is a crucial etiological factor for cervical cancer (CC) development. From a diagnostic view-point, the consistent presence of HPV in CC allows the viral DNA to be used as a genetic marker. The aims of this study were to evaluate the presence, physical status and clinical significance of HPV DNA in circulation of CC patients.

Results: Whereas 6 out of 50 (12%) HPV positive CC patients revealed plasma HPV DNA, it was detected in none of 20 normal controls or 13 HPV negative CC cases. The plasma DNA exhibited an HPV type identical to the HPV in the primary tumors and the DNA from both sources was integrated into host genome. Interestingly, several findings suggested an association between plasma HPV DNA and metastasis. First, three of the HPV DNA positive cases were CC patients with clinical stage IVB or recurrence with distant metastases ($P = 0.001$, $RR = 15.67$). Second, the amount of plasma HPV DNA from metastatic patients to be three times more than three other patients without metastases. Finally, the later cases had tendency to develop recurrence distant metastases within one year after complete treatment when compared with other HPV associated CC patients with the same stage but without the presence of plasma HPV DNA.

Conclusions: The plasma HPV DNA originated from the CC, was associated with metastasis and could be used as a marker representing the circulating free CC DNA.

Background

Cervical cancer (CC) is one of the most common malignancies in women worldwide, especially in developing countries [1]. Several studies have suggested that human papillomavirus (HPV) initiates and causes endogenous genetic alterations in the progression of CC [2]. First, ep-

idemiological studies have shown that most human CCs harbor the "high risk" HPV types 16, 18, 31 and 33 [3,4]. Second, some HPV proteins such as E6 and E7 interact with human tumor suppressor gene products and change cellular phenotypes [5]. Finally, the integration linearizes HPV DNA between E1 and L1 genes and dis-

rupts the viral E2 gene, which consequently induces expression of E6 and E7 genes [6,7]. This genomic rearrangement is thought to be critical for the transformation and proliferation of the early precursors to these cancers [1]. From a diagnostic viewpoint, the consistent presence of HPV in CC allows the viral DNA to be used as a genetic marker. For example, cervical pre-malignant lesions can be screened for highly sensitive HPV DNA detection technology in cell scrapings [8].

Accumulating lines of evidence have elucidated that there is tumor DNA in patients' circulation. Such DNA can be detected in plasma or serum via specific genetic and epigenetic alterations of the primary tumor. Though the mechanism of this phenomenon is not clear, the presence of tumor DNA in blood may have diagnostic and prognostic value [9,10,11,12]. Interestingly, viral DNA has been documented to occur as tumor DNA in the circulation of patients with primary tumors caused by viral infection. For example, there is a high frequency of hepatitis viral genomes and Epstein-Barr viral (EBV) DNA in the circulation of patients with hepatoma and nasopharyngeal cancer (NPC), respectively [13,14,15]. In addition, the circulating EBV DNA may be an invaluable tool for patient monitoring [15,16]. Since HPV DNA serves as a genetic marker for CC, we tested whether HPV DNA could be detected in the plasma of CC patients and whether it originated directly from tumor cells. Moreover, we determined whether the circulating HPV DNA has any diagnostic and prognostic clinical potential for patients with CC.

Materials and methods

Sample Collection

Primary CC tissues were collected from 63 patients before treatment at King Chulalongkorn Memorial Hospital. The tissues were divided into two parts. The first part was sent for routine histological examination. The second part was immediately stored in liquid nitrogen until further use. All of the tumors were histologically ascertained to be CC and the staging was done according to FIGO criteria. The 63 tumors included stages ranging from I to IV. All patients have been followed for treatment outcome and survival.

Blood samples were obtained by venipuncture from the same patients and 20 healthy blood donors. To obtain plasma, blood specimens in EDTA anticoagulant were centrifuged at 3,300 rpm for 10 min, and the plasma were stored at -20°C before use.

DNA Isolation

CC tissue was treated with SDS and proteinase K at 50°C overnight, followed by phenol/chloroform extraction and ethanol precipitation of DNA. Plasma DNA was pu-

rified on Qiagen columns (Qiamap blood kit; Qiagen, Basel, Switzerland) according to the "blood and body fluid protocol". Plasma (200 µl) was processed using the column and one-tenth of the extracted DNA was then used for PCR analysis.

HPV Detection, Quantitation and Typing

For analysis of the HPV DNA in the plasma from CC patients, HPV E6 gene amplification was performed using a protocol previously described with some modifications [17]. The PCR reaction was in a total volume of 20 µl containing 200 µM of each dNTP, 10 µM Tris-HCl (pH 8.4), 50 mM potassium chloride, 4.0 mM magnesium chloride, 0.5 units of AmpliTaq Gold (Perkin Elmer Cetus), 0.4 µM of WD76 (CGGTTSAACCGAAAMCGG) and WD67 (WGCATGCGGTATACTGTCTC), 0.1 µM of WD66 (AGCATGCGGTATACTGTCTC), WD 72 (CGGTCGGGACCGAAAACGG) and WD154 (TCCGTGTGGTGTGTCTGTC). Additionally, another PCR using 0.3 µM of primers specific for ZP3, a gene on the human X chromosome, were performed to test the quality of DNA [18]. For testing DNA and screening for HPV incidence, one ZP3 primer, and WD72 and WD76, respectively, were end labelled at 37°C for 1-2 h in a total volume of 10 µl containing 10 µM primer, 0.025 mCi [γ -³²P] ATP (Amersham-Pharmacia) at 3000 Ci mmol⁻¹, 10 mM magnesium chloride, 5 mM DTT, 70 mM Tris-HCl (pH 7.6) and 10 units of T4 polynucleotide kinase (New England Biolabs). Without further separating of the unincorporated nucleotides, the kinase reaction was added to the PCR buffer mix. The PCR amplifications were performed as follows: initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 1 min, annealing at 55°C for 1 min, extension at 72°C for 2 min and a final extension at 72°C for 7 min. Reaction products were mixed with loading buffer and loaded onto a 4% non-denaturing polyacrylamide gel. DNA fragments were size fractionated at 800 V until the tracking dye had covered the appropriate distance of the gel. After electrophoresis, the wet gel was transferred to filter paper (Whatman), wrapped with Saran wrap and exposed to a phosphorus screen; the bands were visualized on PhosphorImager using ImageQuaNT software (Molecular Dynamics). E6 and ZP3 primer pairs yielded 243 and 177 bp PCR products, respectively. For HPV typing, 50 µl of unlabeled PCR product was prepared for dot blot experiments. All HPV DNA positive plasma and some tumor DNA samples were measured semiquantitatively by performing duplex radiolabeled E6 and ZP3 primer PCR and repeating the above PCR reaction [18]. The difference between viral and host genome copy numbers was calculated from the relative intensity of PCR bands by the imageQuaNT software (Molecular Dynamics).

Table 1: Plasma HPV DNA in tumor, Clinical staging, and treatment outcome of 50 HPV associated CC patients

		Total	Plasma HPV DNA	
			Positive	Negative
Cervical Cancer patient		50	6	44
Age ^a	<50	25	3	22
	>50	25	3	22
HPV type	U ^b	4	0	4
	16	28	2	26
	18	16	4	12
	33	2	0	2
Stage	IB	2	0	2
	IIB	17	3	14
	IIIB	28	0	28
	IVB	1	1	0
	R ^c	2	2	0
IIB response to radiotherapy	PR ^d	3	2	1
	CR ^e	15	1	13
IIB clinical outcome within one year after complete treatment				
R ^c		6	2	4
NED ^f		5	0	5
Metastases				
	Positive	3	3	0
	Negative	47	3	44
Histopathology type	Squamous	42	5	37
	Adenomatous	8	1	7

^a<50 and >50 age less than 50, and above 50, respectively; ^bU, unknown; ^cR, recurrence; ^dPR, partial response; ^eCR, complete response; ^fNED, no evidence of disease

E6 type-specific probes were used for HPV typing. Positive controls of HPV type 6, 11, 16, 18, 31 and 33 from each PCR amplification were included [17]. Products obtained from another unlabeled E6 PCR reaction were heated to 95°C and thereafter 1 volume of 20 X SSC was added. Aliquots of 40 µl were applied to a Hybond-N⁺ nylon membrane (Amersham Pharmacia Biotech) under vacuum, prewetted in denaturing solution (1.5 M NaCl, 0.5 M NaOH). The membranes were transferred to a filter paper soaked in neutralizing solution (1.5 M NaCl, 0.5 M Tris-HCl pH 7.2, 0.001 M EDTA) for 1 min. The membranes were air dried at room temperature, soaked in 0.4 M NaOH for 20 min for fixation and washed with 5 X SSC. Prehybridization at 65°C for 1 h was carried out using 6 X SSC, 5 X Denhardt's solution, 0.5% SDS and

100 µg of single-stranded sheared salmon sperm DNA per ml. Replicate membranes were separately hybridized with denatured ³²P-labelled, type-specific probes in prehybridizing solution for 1 hr at 55°C. Probes WD170 (GCAAGACATAGAAATAA) required hybridization at 45°C. Filters were rinsed briefly in 2 X SSC and 0.1% SDS at room temperature and then twice for 10 min at 45°C (WD170), 50-52°C (WD132 (GACAGTATTGGAACCTTACAG), RR1 (GTACTGCACGACTATGT) and RR2 (ACCTTTGCAACGATCTG)), 55-56°C (WD103 (CAACAGTTACTGCGACG), WD165 (AAATCCTGCAAGAAAGACCTC) and WD166(CCTACAGACGCCATGT-TCA)), or 56-57°C (WD133 (ACACCTAAAGGTCCTGTTTC) and WD134 (ACACTCTGCAAATTCAGTGC)). The membranes were exposed to a

phosphorus screen and the signals were visualized on a PhosphorImager using ImageQuaNT software (Molecular Dynamics).

Detection of HPV Integration by PCR

All DNA samples from plasma and tissue that were positive for HPV type 16 and 18 were analyzed in two PCR reactions. One used 0.5 μ M of each primer (5' E2 consensus primer HPV-16/18 5'-ATGAAAATGAYAG-TAMAGAC-3', 3' E2 primer HPV-16 5'-CCAGTA-GACACTGTAATAG-3' and HPV-18 5'-CATTGTCATGTATCCACC-3'), with 32 P-labelled HPV-16/18 to detect 1026 and 1028 bp PCR products from HPV 16 and 18 episomal forms, respectively [7]. The other used 0.5 μ M of each primer of *PiGR* gene (*PiGR*-F 5'-TCAGCCAGGGTAAGGATCC-3' and *PiGR*-R 5'-TGATGGTCACCGTTCTGCC-3') to amplify a 1392 bp fragment of human genomic DNA as a control. The PCR reactions contained 200 μ M dNTP each, 10 μ M Tris-HCl (pH 8.4), 50 mM potassium chloride, 1.5 mM magnesium chloride, 0.5 units of *Thermus aquaticus* DNA polymerase (Perkin Elmer Cetus), and the PCR amplifications were performed as follows: initial denaturation at 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 1 min, annealing at 45°C for E2 gene or 55°C for *PiGR* for 1 min, extension at 72°C for 3 min and a final extension at 72°C for 7 min. Reaction product was mixed with loading dye and loaded onto 4% non-denaturing polyacrylamide gel. DNA fragments were size fractionated at 800 V until the tracking dye had covered the appropriate distance of the gel. After electrophoresis, the wet gel was transferred to filter paper (Whatman), wrapped with Saran wrap and exposed to a phosphorus screen. The bands were visualized on a PhosphorImager using ImageQuaNT software (Molecular Dynamics).

Correlation between Clinical Data and Plasma HPV DNA

Data regarding histology, tumor staging, clinical phenotypes, treatment outcome, and HPV PCR and typing were collected in a double-blind fashion until analyzed. The Fisher's exact test was used to compare the results obtained from plasma analysis with those of HPV and clinical parameters.

Results

HPV DNA in Plasma


To determine whether HPV DNA could be detected in the circulation of CC patients and represented tumor DNA, DNA from the plasma of three groups was studied. The first two comprised 63 positive and negative HPV CC patients, and the other 20 healthy female blood donors. The patients included in this study, were classified by age, pathological structure, and stage (Table 1). The control marker, ZP3, was positive in all samples. As a result, all were further analyzed for the presence of HPV DNA

by PCR using labeled E6 degenerate primers. Plasma HPV DNA was a specific genetic marker for HPV associated CC, since it was detectable from neither HPV negative CC nor normal controls. Nevertheless, the circulating DNA had low sensitivity. Only 6 out of 50 (12%) with HPV associated CC patients were demonstrated to have circulating HPV DNA (Fig 1A and Table 1).

The frequency and type of HPV DNA were reevaluated from all plasma and tumor samples by PCR using the E6 degenerate primers and dot blot hybridization using type specific oligonucleotides (Fig 1B and Table 1,2). The presence of HPV DNA status was confirmed and plasma HPV DNA showed the same viral type as the tumors. Furthermore, DNA from both plasma and tumor from the 6 plasma-positive cases were differentiated between integrated and episomal. Since the integration process disrupts the HPV E2 gene, PCR using radioactive labeled E2 primer would show positive result from episomal form of HPV but negative if the DNA integrated (Fig 1C). Whereas E2 PCR product was detectable in 20.75% of the HPV positive tumors, none of the plasma or tumor samples from plasma HPV DNA positive CC patients was positive (Fig 1D). In consideration with the absence of episomal HPV DNA from tumor, it is most likely that the negative E2 PCR result was due to plasma HPV DNA derived from integrated HPV genome. This observation suggested that the circulating free HPV DNA originated from the CC and thus could be used as a marker for tumor DNA.

Plasma HPV DNA and Clinical Correlation

To elucidate the importance and meaning of CC DNA present in plasma, the correlation between the presence and amount of plasma HPV DNA and clinical data was investigated (Table 1). Clinical data including age, staging, metastasis, response to treatment, and site of recurrence of plasma HPV DNA positive patients were included in Table 2. Interestingly, there was an association between plasma HPV DNA and metastasis. Three out of six plasma HPV DNA positive patients but none of the other patients with HPV associated cancers had distant metastasis at the time of blood analysis ($P < 0.001$, $RR = 15.67$ ($5.24 < RR < 46.83$)). One of the three was stage IVB and two had a recurrence distant metastasis, one of whom had previously been plasma HPV DNA negative at stage IIIB. In addition, we evaluated the amount of HPV DNA in circulation by semi-quantitative PCR, comparing the intensity of PCR products between HPV E6 gene and ZP3, a gene on the human X chromosome. The average intensity ratio between these two bands from tumor DNA and plasma DNA samples was one and 0.08, respectively (Fig 1E and Table 2). Plasma from one of the patients, 106, was collected twice at dif-

**Figure 1**

HPV DNA in plasma of patients with cervical cancer. (A) PCR generating 243-bp DNA fragments of HPV E6 gene (B) Dot-blot hybridization for HPV 18 probe Lanes a1-f1 were positive controls using purified plasmids of HPV type 6, 11, 16, 18, 31 and 33, respectively Lanes a2-f2 were plasma DNA from patients number 4, 106, 148, 161, 183, and 59 respectively Lanes a3-f3 were tumor DNA from the same patients as lanes a2-f2 (C) PCR generating 1392- and 1028-bp DNA fragments of human *PIGR* genomic sequence and HPV-18 E2 (D) PCR generating 1026, 1028-bp DNA fragments of HPV 16 and 18 E2 gene, respectively, from tumor DNA on a 2% agarose gel stained with ethidium bromide (E) Duplex PCR generating 243- and 177-bp DNA fragments of HPV E6 gene and human *ZP3* genomic sequence, respectively From left to right of A, C-E: M, 100-bp ladder standard DNA size marker; - and +, PCR products of the negative control (double-distilled water) and positive control (Hela cell line for A and E; purified plasmids for D; and for C, DNA from human leukocyte for *PIGR* and purified HPV 18 DNA plasmid for E2 gene), respectively; numbers without p indicate PCR products of tumor DNA; numbers with p indicate PCR products of plasma DNA of CC patients Number 1061p and 1062p were plasma DNA from patient 106 but the samples were collected at different time

ferent time and demonstrated the identical ratio (Fig 1E). Furthermore, the ratios from the three plasma samples of patients with metastases, 0.05, 0.14, and 0.19, was higher, though not statistically significant, $p = 0.098$, than from the other three non-metastasis patients, 0.02, 0.04, and 0.05. Interestingly, the three plasma HPV DNA positive patients who were stage IIB did not have as good a clinical outcome when compared with the other plasma HPV DNA negative patients with the same stage. Whereas 13 out of 14 plasma negative cases had a complete response to radiotherapy, 2 out of the 3 circulating viral DNA positive cases were partially resistant. However, formal comparison did not yet show significant statistical value, $p = 0.063$. In addition, we found that plasma HPV DNA positive patients may have tendency to develop recurrent disease. In patients who was followed up for more than one year, 2 out of 2 and 4 out of 9 plasma HPV DNA positive and negative patients, respectively, suffered reappearance of CC.

Discussion

The results of the present investigation confirm that it is possible to identify HPV DNA in DNA extracted from the plasma of patients with CC. More importantly, there are at least three findings suggesting that the viral DNA most likely originates from the tumor itself. First, circulating HPV DNA was not present in normal controls or HPV negative CC. In addition, all HPV DNA derived from HPV-associated CC patients' circulation was type 16 or 18. These high-risk HPV types are frequently associated with high-grade cervical intraepithelial neoplasia and CC [4,19]. Second, the plasma DNA exhibited an HPV type identical to the primary tumors in the patients. Thus the possibility that HPV DNA in circulation is derived from another latent epithelial infection was remote. Finally, the HPV genomes from both tumor and plasma were revealed the same physical status by inte-

grating into the host genome. This was a unique characteristic for CC development and confirmed that the circulating viral DNA was from cancer cells [6,7].

Though both NPC and CC are viral associated lymphoepithelioma, squamous epithelial tumor with heavily lymphocyte infiltration, the incidence and physical status of viral DNA in the circulation and in tumors suggests that the DNA is released into the circulation of NPC and CC patients via a different mechanism. A much higher frequency of circulating EBV DNA has been discovered in NPC [15,16]. In addition, serum EBV DNA is resistant to Dnase treatment [15]. In conjunction with the expression and high antibody titer of lytic replication genes in NPC patients, it is likely that some circulating EBV DNA in NPC is virion associated [15,20,21]. In contrast to EBV, at least two lines of evidences indicated that plasma HPV DNA was free DNA, not virion-associated. First, the clinical phenotype associated with circulating DNA was similar between head and neck squamous cell cancer (HNSCC) and CC. A recent study used human promoter hypermethylation as a serum marker and demonstrated an association between this epigenetic marker and metastasis [22]. In addition, circulating HPV DNA could be found in a low percentage and associate with metastasis not only of CC cases but also of HNSCC cases where the primary tumor harbors HPV DNA [23]. The other reason that argues against the possibility that circulating HPV DNA is virion-associated is that the viral genome has integrated into the host genome with consequent deletion of part of the HPV genome. This physical characteristic is unique to HPV carcinogenesis and prevents viral ability to undergo complete lytic replication. All this evidence suggested that the mechanism by which viral DNA is released into the circulation of NPC and CC, although both are viral associated squamous epithelial cancers, is distinct.

Table 2: Clinical parameters and HPV characteristics of 6 plasma HPV DNA positive CC patients

Patient Code	Age	Stage ^a	Pathology Type	Tumor Size (cm)	Response to Radiotherapy	Time Recur (month) ^b	Metastatic Organ	HPV type	Relative amount of E6:ZP3 PCR ^f
4	39	IIB	Adenomatous	7	Partial			18	0.02
148	65	IIB	Squamous	3	Complete	8	Pleura,	18	0.04
							Peritoneumc		
183	27	IIB	Squamous	6	Partial	11	Bone ^c	18	0.05
106	51	IVB	Squamous	>4			Liver, Pleurad	18	0.14
161	34	R ^e	Squamous	7			Umbilicusc ^d	16	0.19
59	46	R ^e	Squamous	5			Liver, Lung ^d	16	0.05

^a Stage at the time of blood examination; ^b Time for recurrence after complete treatment; ^c Metastasis at time of recurrence; ^d Metastasis at time of plasma DNA analysis; ^e R, recurrence; ^f Average amount from two experiments

This study indicated that plasma HPV DNA was a specific, but not a sensitive, genetic marker for CC diagnosis. More importantly, there was a strong association between plasma HPV DNA and metastasis, both when considering incidence and amount of the circulating viral DNA. Plasma HPV DNA positive non-metastatic CC patients had tendency toward poor clinical outcome and development of recurrent distant metastasis. This was not surprising. Although a variety of studies have shown that patients with very early stage disease can harbor free circulating tumor DNA, several reports have revealed plasma tumor DNA to be more commonly detectable in advanced stage disease, to correlate inversely with clinical outcome and to correlate with a tendency to fail with effective treatment [9,22,23,24,25,26]. There were at least three possible explanations for the association between plasma CC DNA and metastasis. The most common hypothesis is that circulating cancer DNA due to the lysis of circulating cancer cells or micrometastasis shed by the tumor. HPV-specific mRNA has been found in peripheral blood cells, circulating micrometastatic CC cells, and lymph nodes of advanced-stage CC patients with metastasis [27,28]. Nevertheless, a study of the relative amount of DNA in the plasma of pancreatic cancer patients indicated that a number of circulating cancer cells was insufficient and rejected this hypothesis [29]. Second, some in vitro and vivo studies have suggested that circulating tumor DNA in plasma might play a role in metastasis because of its high transforming activity [30,31]. Finally, because there is a tendency toward poor clinical outcome for plasma HPV DNA positive CC patients, the mechanism to actively release tumor DNA into circulation might occur late during the multistep process of CC development when metastasis is more likely [10]. Regardless of the mechanisms, our data show that plasma HPV DNA in viral associated CC should be an independent genetic marker to predict disease progression and clinical outcome.

Conclusions

The results of the present investigation indicated that it was possible to identify HPV DNA in DNA extracted from the plasma of some patients with CC. More importantly, The HPV genomes from both tumor and plasma were revealed the same type and physical status by integrating into the host genome. Thus the viral DNA most likely originated from the tumor itself and the plasma HPV DNA represented the circulating free cell CC DNA. Finally, plasma HPV DNA was a specific, but not a sensitive, genetic marker in which strongly associated with CC metastasis.

Acknowledgements

We are indebted to all staffs in the Department of Obstetrics and Gynecology and the Division of Radiation Oncology, Department of Radiology, Chulalongkorn University Hospital, who provided all clinical samples; and

to Ms Salroong Sakdikul for technical assistance. This work was supported by the Molecular Biology Project, Faculty of Medicine, Chulalongkorn University, and the Thailand Research Fund.

References

1. Cannistra SA, Niloff JM: Cancer of the uterine cervix. *N Engl J Med* 1996, 334:1030-1038
2. Lazo PA: The molecular genetics of cervical carcinoma. *Br J Cancer* 1999, 80:2008-2018
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. *J Natl Cancer Inst* 1995, 87:796-802
4. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK, Manos MM: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. *J Natl Cancer Inst* 1993, 85:958-964
5. Kubbutant MHG, Vousden KH: Role of E6 and E7 oncoproteins in HPV-induced anogenital malignancies. *Semin Virol* 1996, 7:295-304
6. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM: Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. *J Virol* 1987, 61:962-971
7. Park JS, Hwang ES, Park SN, Ahn HK, Um SJ, Kim CJ, Kim SJ, Namkoong SE: Physical status and expression of HPV genes in cervical cancers. *Gynecol Oncol* 1997, 65:121-129
8. Cuzick J: Human papillomavirus testing for primary cervical cancer screening. *JAMA* 2000, 283:108-109
9. Sidransky D: Circulating DNA: What we know and what we need to learn. *Ann N Y Acad Sci* 2000, 906:1-4
10. Stroun M, Maurice P, Vasioukhin V, Lyatuey J, Lederrey C, Lefort F, Rossier A, Chen XQ, Anker P: The origin and mechanism of circulating DNA. *Ann N Y Acad Sci* 2000, 906:161-168
11. Jen J, Wu L, Sidransky D: An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. *Ann N Y Acad Sci* 2000, 906:8-12
12. Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. *Cancer Metastasis Rev* 1999, 18:65-73
13. Muirangura A, Pornthanakasem W, Theamboonlers A, Sriuranpong V, Lertsanguansinchi P, Yenrudi S, Voravud N, Supiyaphun P, Poovorawan Y: Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. *Clin Cancer Res* 1998, 4:665-669
14. Tangkijvanich P, Hirsch P, Theamboonlers A, Nuchprayoon I, Poovorawan Y: Association of hepatitis viruses with hepatocellular carcinoma in Thailand. *J Gastroenterol* 1999, 34:227-233
15. Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N, Muirangura A: Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. *Clin Cancer Res* 2000, 6:1046-1051
16. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP: Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. *Cancer Res* 1999, 59:1188-1191
17. Resnick RM, Cornelissen MT, Wright DK, Eichinger GH, Fox HS, ter Schegget J, Manos MM: Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. *J Natl Cancer Inst* 1990, 82:1477-1484
18. Cul KH, Warnes GM, Jeffrey R, Matthews CD: Sex determination of preimplantation embryos by human testis-determining gene amplification. *Lancet* 1994, 343:79-82
19. de Villiers EM: Heterogeneity of the human papillomavirus group. *J Virol* 1989, 63:4898-4903
20. Martel-Renol D, Grunewald V, Toutou R, Schwaab G, Joab I: Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. *J Gen Virol* 1995, 76:1401-8
21. Joab I, Nicolas JC, Schwaab G, de-Thoe G, Clausse B, Perricaudet M, Zeng Y: Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. *Int J Cancer* 1991, 48:647-649

22. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. *Cancer Res* 2000, 60:892-5
23. Caone RB, Pal SI, Koch WM, Gillison ML, Danish HN, Westra WH, Daniel R, Shah KV, Sidransky D: Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. *Clin Cancer Res* 2000, 6:4171-5
24. Fujiwara Y, Chi DD, Wang H, Keleman P, Morton DL, Turner R, Hoon DS: Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. *Cancer Res* 1999, 59:1567-1571
25. Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, Provencio M, San Martin S, Espana P, Bonilla F: Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. *Cancer Res* 1999, 59:3251-3256
26. Yamada T, Nakamori S, Ohzato H, Oshima S, Aoki T, Higaki N, Sugimoto K, Akagi K, Fujiwara Y, Nishisho I, Sakon M, Gotoh M, Monden M: Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. *Clin Cancer Res* 1998, 4:1527-32
27. Pao CC, Hor JJ, Yang FP, Lin CY, Tseng CJ: Detection of human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis. *J Clin Oncol* 1997, 15:1008-1012
28. Czegledy J, Iosif C, Hansson BG, Evander M, Gergely L, Wadell G: Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer? *Int J Cancer*. 1995, 64:211-5
29. Sorenson GD, Porter DM, Barth RJ, Memoli VA, Rhodes CH, Karagas M, Tosteson TD, Bzik DJ: Detection of mutated KRAS2 sequences in plasma from patients with pancreatic carcinoma in comparison with the Cal 9-9 assay. *J Int Soc Oncodev Biol Med* 1997, 18:66-
30. Anker P, Lyautey J, Lefort F, Lederrey C, Stroun M: Transformation of NIH/3T3 cells and SW 480 cells displaying K-ras mutation. *C R Acad Sci III* 1994, 317:869-74
31. Garcia-Olmo D, Garcia-Olmo DC, Ontanon J, Martinez E, Vallejo M: Tumor DNA circulating in the plasma might play a role in metastasis: the hypothesis of the genomestasis. *Histopathol* 1999, 4:1159-1164

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/content/backmatter/1471-2407-1-2-b1.pdf>

Publish with **BioMedcentral** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright



BioMedcentral.com

Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>

editorial@biomedcentral.com

Serum/Plasma Viral DNA

Mechanisms and Diagnostic Applications to Nasopharyngeal and Cervical Carcinoma

APIWAT MUTIRANGURA

Genetics Unit, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

ABSTRACT: Following reports describing circulating tumor DNA, serum/plasma viral nucleic acid has shown its potential as a new diagnostic target in cancer. In the majority of examples of viral carcinogenesis, the viral genome is consistently present in certain tumors and serves as an effective marker. This article reviews recent findings, proposes possible mechanisms, and examines the potential clinical application of serum/plasma Epstein-Barr virus (EBV) DNA in nasopharyngeal cancer (NPC) and human papillomavirus (HPV) DNA in cervical carcinoma (CC). These tumors share a DNA viral etiology and present similar histopathological findings. However, plasma EBV and HPV DNA are distinct in several aspects, including incidence, mechanism of release from tumor, and clinical application. Both circulating cell-free EBV and HPV DNA reveal the same viral type as their matched tumors, indicating both are derived from the neoplastic tissue. Plasma viral DNA incidence and copy number are high in NPC, but low in HPV-associated cancers. Whereas much EBV DNA in NPC is episomal, the resistance to DNase treatment of serum EBV DNA and evidence confirming lytic EBV replication in NPC suggest that a reasonable proportion of plasma EBV DNA is virions. On the contrary, plasma HPV genomes, as in CC, integrate into host chromosome. Plasma EBV DNA copy number, by quantitative PCR, is related to tumor mass, predicts prognosis, measures immediate response to treatment, and is useful in early detection of recurrence. Plasma HPV DNA, on the other hand, is associated with and can be considered as an early tumor marker for distant metastasis.

KEYWORDS: Serum/plasma viral DNA; Nasopharyngeal cancer; Cervical cancer; Human papillomavirus; Epstein-Barr virus

INTRODUCTION

Plasma or serum DNA has become the most promising circulating tumor marker during the last decade.^{1,2} However, the genetic heterogeneity of cancer complicates its use since a number of different genetic markers are required to evaluate each patient.^{1,2} Viral DNA, on the other hand, is more simple since viruses are the cause of particular types of neoplastic development and progression. Consequently, viral

Address for correspondence: Apiwat Mutirangura, Genetics Unit, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. Voice: 66-2-256-4532; fax: 66-2-256-4534.
mapiwat@chula.ac.th

TABLE 1. Correlation between nasopharyngeal and cervical carcinoma

		Nasopharyngeal cancer	Cervical cancer
Incidence		High in southern China, but rare in most other parts of the world	Worldwide
Histology	Normal tissue lining	Transitional zone (junction changing from pseudostratified columnar to stratified squamous epithelium)	Transitional zone (junction changing from simple columnar to stratified squamous epithelium)
	Histopathology	Mostly poor or undifferentiated squamous cell cancer with heavy lymphocytic infiltration	Mostly squamous cell cancer and some with heavy lymphocytic infiltration
Etiological factor	DNA virus	Epstein-Barr virus	Human papillomavirus
	Viral life cycle	Systemic (infects B lymphocytes and nasopharyngeal epithelium)	Local (infects, replicates, and reinfects cervical epithelium)
	Viral physical status in cancer cells	Mostly episomal form	Mostly integrated form
	Viral oncogenesis	Expresses viral oncogenes	Expresses viral oncogenes

DNA is a specific and sensitive marker for viral-associated cancers.³ Nasopharyngeal cancer (NPC) and cervical cancer (CC) are important epithelial malignancies with DNA viral etiology and present similar histopathology findings (TABLE 1). Most cases of NPC and a majority of CC are squamous cell carcinoma. In addition, some CCs are lymphoepitheliomas, a squamous epithelial tumor with heavy lymphocytic infiltration that is strikingly similar to NPC.⁴ This article reviews recent reports of circulating cell-free Epstein-Barr virus (EBV) DNA in NPC and plasma human papillomavirus (HPV) DNA in CC (TABLE 2). In addition, possible distinct mechanisms and potential uses as circulating tumor markers of both viral DNA types will be discussed.

NPC AND CC

Both NPC and CC are significant problems in world health (TABLE 1). NPC, although rare in most parts of the world, constitutes an important cancer in Asia, most frequently encountered in southern China (30–50 cases per 100,000 people/year). An intermediate incidence is observed in Southeast Asia (3–10 cases per 100,000 people/year). Other ethnic groups showing a higher incidence are Eskimos of the Arctic region and some North and East African populations.⁵ EBV appears to be the most important etiological factor in NPC.⁶ The viral genome is clonal in origin and detectable in almost all NPC tissues.⁷ CC, on the other hand, is one of the

most common tumors affecting women worldwide, in both incidence and mortality, with approximately 471,000 new cases/year diagnosed globally.^{8,9} Almost all CCs are associated with some specific types of HPV.^{9,10} From a diagnostic viewpoint, the consistent presence of EBV in NPC and HPV in CC allows viral DNA detection to be used in clinical diagnosis. For example, the positive detection of EBV by PCR from a cervical lymph node with a metastatic tumor of unknown origin can be confidently diagnosed as a case of NPC.¹¹ Regarding CC, cervical premalignant lesions can be screened for HPV DNA in cell scrapings using highly sensitive DNA detection technology.¹²

BOTH PLASMA EBV AND HPV DNA ARE DERIVED FROM TUMOR

There are several potential sources of EBV DNA in the circulation since EBV can latently infect a number of cell types, particularly B lymphocytes.^{3,6} However, plasma EBV DNA in NPC has been shown to be derived from the tumor. In general, primary infection with EBV occurs early in life. The virus primarily infects the oropharyngeal epithelium. The EBV then replicates, lyses, and infects B lymphocytes. After infection, the virus enters the lytic phase and causes diseases ranging from a mild self-limiting illness to infectious mononucleosis. However, in some cells, the virus enters the latent phase. These latently infected B lymphocytes have the ability to lead to malignancies, such as B cell lymphomas of the immunosuppressed, Burkitt's lymphoma, and Hodgkin's disease. This latent virus can play another important role in the dissemination of EBV infection within the nasopharynx. With subsequent host genome mutations, NPC may develop.^{6,13} Thus, plasma EBV DNA can be derived from lymphocytes and detectable in some people as an indicator for active EBV infection.¹⁴ Nevertheless, several lines of evidence suggest that EBV DNA discovered in the plasma of NPC patients derives from the tumor.¹⁵ First, EBV DNA is frequently detectable in the plasma of NPC patients (70% and 96%), but rare in normal people (13% and 7%) by nested and quantitative PCR, respectively.^{16,17} Second, in contrast to that due to lytic replication from lymphocytes, EBV DNA from NPC patients is continuously present before treatment.¹⁶ Third, comparison between EBV typing in primary tumors and matched patient sera shows identical results.¹⁵ Finally, plasma EBV DNA disappears from patients showing complete response to radiotherapy.^{16,17}

HPV, on the contrary, can be considered as a local viral infection.³ The papilloma-viruses are highly species-specific and have a specific tropism for squamous epithelial cells. The viruses also induce squamous epithelial tumors and fibroepithelial tumors in their natural hosts.³ Viral replication can persist within the basal cell layer of the epithelium. High-risk HPV types (16, 18, 31, and 33) will synthesize viral oncoproteins, especially E6 and E7, usually by integrating its 8-kb genome into host DNA. This process linearizes HPV DNA between the E1 and L1 genes and disrupts the E2 gene. As a result, expression of the E6 and E7 genes are not suppressed.^{3,9} Recently, we reported HPV DNA typing in the plasma of CC patients in comparison with their matched tumors.¹⁸ Whereas no HPV DNA could be detected from the circulation of normal controls and HPV-negative CC, an incidence of 12% was demonstrated in the plasma of HPV-associated CC patients. In addition, all positive cases revealed the same HPV type as found in the primary cancers. Thus, plasma

HPV DNA could be identified from HPV-associated CC and the DNA was shown to originate from the cancer cells.

DISTINCT VIRAL DNA RELEASING MECHANISMS BETWEEN NPC AND CC

A high incidence (70–96%) and copy number (4000–90,000 copies/mL) of plasma EBV DNA from patients with NPC suggest a unique mechanism for tumor release.^{16,17} There are at least three possible mechanisms for this process, in which all may be responsible together in the presence of plasma EBV DNA. Two lines of evidence support cell death as one mechanism. There is a weak correlation between the presence of serum EBV DNA and apoptosis,¹⁵ and there is a rise in plasma EBV DNA concentration after initiation of radiotherapy-induced cell death.¹⁹ The second possible mechanism would be a consequence of the EBV genome remaining in NPC in an episomal form. Chen *et al.* demonstrated that extrachromosomal DNA could be induced in human lymphocytes by treating with phytohemagglutinin *in vitro*.²⁰ More importantly, this DNA could be detected not only in the nucleus, but also in the cytoplasm. This finding has led to the proposition that induction of such small fragmented DNA might be another mechanism of tumor DNA release because of the small size and its lack of specific structures, such as the centromere, for it to be retained in the nucleus. This hypothesis is very interesting since genome of cancer cells is prone to contain small fragmented DNA caused by double-strand breaks²¹ or double minute chromosomes from oncogene amplification.²² In more than 76% of NPC, the viral genome is not integrated and remains in an episomal form.²³ Consequently, the EBV DNA may be more easily released from the NPC cells.

The third possible mechanism for EBV DNA to be released into NPC patient circulation is lytic replication. In this case, a reasonable proportion of the circulating EBV DNA should be in the form of virions. Most EBV DNA from NPC patients' sera, unlike human genomic DNA, resists DNase treatment.¹⁶ Thus, at least some of the viral DNA is encapsulated. The presence of virus in the circulation of NPC patients is surprising because the majority of EBV in NPC cells should be in the latent phase, as shown by EBV clonal studies.⁷ Consequently, serum/plasma EBV DNA should present solely as free nucleic acid. Nevertheless, our data invite the hypothesis that some EBV in NPC has entered lytic replication. This could explain why antibody titers to lytic cycle antigens, such as the viral capsid antigen and BZLF1 immediate-early gene product ZEBRA, rise in NPC patients.^{24,25} A recent study has shown that IgG antibodies directed against the BRLF1 immediate-early gene protein product, Rta, are detectable in 83% of NPC plasma samples.²⁶ In addition, expression of the immediate-early BZLF1 and BHLF1 genes or ZEBRA protein is frequently detectable in NPC.^{26–28} Our ongoing research has discovered mRNA of the late lytic replication gene, BLLF1, by reverse transcriptase PCR in these cases. This confirms that there are active genes from all the viral lytic replication phases required for replicating EBV in NPC. There may only be a small proportion of cells entering lytic replication or most of virions may be released from NPC cells. Thus, studying the clonal progression of EBV by analyzing terminal repeat lengths using Southern blot hybridization may not be sensitive enough to detect lytic replication or the results might be interpreted as contaminants and hence be ignored.

Definitive proof, such as electron microscopic analysis and characterization of the physical appearance of EBV in patients' plasma is required.

Circulating free-cell HPV DNA from CC is different from plasma EBV DNA from NPC in both physical status and incidence. We have recently reported that a low proportion of HPV-positive CC patients, 6 out of 50 (12%), revealed plasma HPV DNA, and the DNA from both plasma and tumor was integrated into the host genome.¹⁸ The low plasma HPV DNA incidence is controversial. Three groups (Sidransky *et al.*,²⁹ Pornthanakasem *et al.*,¹⁸ and Duenas *et al.*³⁰) reported the discovery of plasma HPV DNA, but with different detection rates. Studies in the United States and Thailand demonstrated 6% and 12% of plasma HPV DNA from CC patients, respectively.^{18,29} However, an incidence of over 70% was shown from a study in Mexico.³⁰ This difference may have been due to technical factors. Nevertheless, a number of lines of evidence support the low incidence. First, two groups, in the United States and Thailand, showed the same finding by different experimental approaches. Second, in addition to incidence, our data have demonstrated a strong statistical correlation between the presence of plasma HPV DNA and distant metastasis ($p = 0.001$).¹⁸ This correlation would be unlikely if positive results were obscured by poorly sensitive or erroneous techniques. In addition, this correlation with metastasis was also supported in head and neck squamous cell cancer patients with positive plasma HPV DNA.³¹ Finally, the presence or absence of plasma HPV DNA is not altered when repeatedly evaluating the same patient using different times of sample collection before treatment. This consistency would not be likely without an accurate detection method.

Regarding our recent study, among the 50 patients with HPV-associated CC, 20.75% revealed episomal HPV genome in their tumors.¹⁸ Interestingly, in all 6 cases with positive plasma HPV DNA, no episomal DNA could be demonstrated in both tumor or plasma. Hence, all plasma HPV DNA was in an integrated form and thus should be free DNA. This lack of plasma HPV DNA from tumors with episomal virus does not support the extrachromosomal hypothesis discussed above. In addition, the low incidence of HPV DNA in circulation and the low copy number (1–35 copies/mL) of head and neck cancer plasma HPV DNA suggest that,³¹ unlike EBV, there is no or a less efficient mechanism for releasing HPV DNA into the circulation.

VIRAL DNA IS A CIRCULATING TUMOR MARKER

High sensitivity and specificity have led to circulating EBV DNA becoming a useful tumor marker, especially for patient follow-up (TABLE 2). NPC is a form of cancer with a high success rate of radiochemotherapy. However, many cases may recur, even after very long periods of latency. Consequently, most NPC patients require very consistent long-term follow-up. Some of them may require expensive investigations, such as computed tomography scanning or invasive methods, especially punch biopsy. Analyzing serum/plasma EBV DNA is an inexpensive and noninvasive technique suitable for clinical monitoring. Whereas a very high incidence and amount of plasma EBV DNA are shown prior to treatment, the DNA disappears after completion of radiotherapy in patients with a complete response. The plasma DNA reappears or persists in cases of recurrence or incomplete response to treatment.¹⁶ Circulating EBV DNA may thus be used to determine the effectiveness

TABLE 2. Correlation between serum/plasma EBV DNA in NPC and HPV DNA in CC

	EBV DNA in NPC	HPV DNA in CC
Origin	Tumor cells	Tumor cells
Incidence	70–96%	6%, 12%, 70% ^a
Copy number	4000–90,000 copies/mL	1–35 copies/mL ^b
Physical status	Virus and episome	Integrates into host genome
Proposed releasing mechanism	Lytic replication, cell death, and episomal DNA	Tumor DNA and associated with metastasis
Diagnostic application	Quantitative PCR for prognosis, immediate response to treatment, and early detection of recurrence	Tumor marker for distant metastasis

^aReferences 29, 18, and 30, respectively.^bPlasma HPV DNA in head and neck squamous cell cancer.³¹

of treatment. For most patients, circulating viral DNA disappears within three weeks after initiation of radiotherapy. A few patients show persistent or reappearing DNA during the later period of treatment. These later groups may reflect tumor resistance or metastasis.¹⁶ The usefulness of serum/plasma EBV DNA as a molecular marker for patient monitoring is most effective when analyzed quantitatively. This PCR technique provides more detailed information of viral load, which is related to tumor mass. Thus, quantification of plasma EBV DNA yields better information not only regarding tumor recurrence, but also concerning the immediate response of treatment and prognosis.^{17,19,32,33}

Unfortunately, the lower incidence of plasma HPV DNA makes the test less attractive. However, the strong association with distant metastasis ($p = 0.001$, $RR = 15.87$) may allow this marker to be useful in this aspect (TABLE 2).¹⁸ This association is not surprising since several reports have revealed plasma tumor DNA to be more commonly detectable in advanced stage disease and metastasis, to correlate with unfavorable clinical outcome, and to be associated with a tendency to fail in treatment.^{1,2,31,34,35} There are at least three possible explanations for the association between plasma CC DNA and metastasis. The most common hypothesis is that circulating cancer DNA is due to the lysis of circulating cancer cells or micrometastases shed by the tumor. Circulating micrometastatic CC cells have been found by analyzing HPV-specific mRNA in peripheral blood cells of advanced stage CC patients with metastasis.³⁶ Second, some *in vitro* and *in vivo* studies have suggested that circulating tumor DNA in plasma might play a role in metastasis because of its high transforming activity.³⁷ Finally, there is a tendency towards poor clinical outcome for plasma HPV DNA-positive CC patients. The mechanism to actively release tumor DNA into the circulation might occur late during the multistep process of CC development when metastasis is more likely.

Detection of plasma HPV DNA may thus be an early sign of distant CC metastasis. In our recent study,¹⁸ 3 out of 6 CC patients found to have plasma HPV DNA had distant metastasis at the time of evaluation. Interestingly, the remaining 3 plasma

HPV DNA-positive patients, who were at stage IIB, did not have as good a clinical outcome when compared with the other plasma HPV DNA-negative patients and developed recurrence of distant metastasis within one year after treatment. Although CC distant metastasis is rare at the time of first admission, it is frequently discovered if the disease recurs. Consequently, plasma HPV DNA may be a useful marker to screen for undetectable metastasis or to monitor patients after treatment.

APPLICATION TO OTHER VIRAL-ASSOCIATED CANCERS

Evaluating circulating viral DNA as a tumor marker can be applied to other malignancies. A similar incidence and condition with treatment of plasma viral DNA to NPC has been reported in EBV-associated lymphoma.³⁸ Thus, the same concepts might be applied to this and other viral-associated cancers. There are other EBV-associated malignancies, that is, gastric cancer or HPV-associated cancers, and malignancies of the upper airway, skin, and anogenital organs. In addition, other DNA and RNA viruses that can cause cancers, such as hepatitis B and C virus and HTLV-1, may also be studied.³ A high frequency of the hepatitis viral genome has been discovered in hepatoma patients.³⁹ Unfortunately, the viral genome is not distinguishable between patients with hepatoma and chronic hepatitis, limiting the usefulness of detecting viral hepatitis DNA as a tumor marker. HTLV-1 infects circulating T lymphocytes;⁴⁰ thus, there is no obvious advantage in using plasma nucleic acid as a diagnostic target for leukemia associated with this virus. Nevertheless, better understanding of how tumors release viral genomes into the circulation may provide a better understanding of the biology of viral carcinogenesis and may lead to future clinical applications.

ACKNOWLEDGMENTS

I am deeply indebted to all research colleagues at Chulalongkorn University Hospital for their excellent contributions. I would also like to thank Robert Oelrichs for critical review of the manuscript. All molecular genetic studies performed in Thailand mentioned in this review were supported by Molecular Biology Projects, Faculty of Medicine, Chulalongkorn University; the Thailand Research Fund; and the National Center for Genetic Engineering and Biotechnology.

REFERENCES

1. ANKER, P. & M. STROUN. 2001. Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis, and detection of minimal residual disease. *Leukemia* 15: 289-291.
2. SIDRANSKY, D. 2000. Circulating DNA—what we know and what we need to learn. *Ann. N.Y. Acad. Sci.* 906: 1-4.
3. HOWLEY, P.M., D. GANEM & E. KIEFF. 1997. DNA viruses. In *Cancer Principles and Practice of Oncology*, pp. 168-184. Lippincott-Raven, Philadelphia.
4. MILLS, S.E. *et al.* 1985. Lymphoepithelioma-like carcinoma of the uterine cervix: a distinctive, undifferentiated carcinoma with inflammatory stroma. *Am. J. Surg. Pathol.* 9: 883-889.

5. FANDI, A. *et al.* 1994. Nasopharyngeal cancer: epidemiology, staging, and treatment. *Semin. Oncol.* 21: 382-397.
6. LIEBOWITZ, D. 1994. Nasopharyngeal carcinoma: the Epstein-Barr virus association. *Semin. Oncol.* 21: 376-381.
7. PATHMANATHAN, R. *et al.* 1995. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. *N. Engl. J. Med.* 333: 693-698.
8. CANNISTRA, S.A. & J. NILOFF. 1996. Cancer of the uterine cervix. *N. Eng. J. Med.* 334: 1030-1038.
9. LAZO, P.A. 1999. The molecular genetics of cervical carcinoma. *Br. J. Cancer* 80: 2008-2018.
10. BOSCH, F.X. *et al.* 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective international biology study on cervical cancer (IBSCC) study group. *J. Natl. Cancer Inst.* 87: 796-802.
11. FEINMESSER, R. *et al.* 1992. Diagnosis of nasopharyngeal carcinoma by DNA amplification of tissue obtained by fine-needle aspiration. *N. Engl. J. Med.* 326: 17-21.
12. CUZICK, J. 2000. Human papillomavirus testing for primary cervical cancer screening. *JAMA* 283: 108-109.
13. MUTIRANGURA, A. *et al.* 1997. Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. *Br. J. Cancer* 76: 770-776.
14. GAN, Y.J., J.L. SULLIVAN & J.W. SIXBEY. 1994. Detection of Epstein-Barr virus DNA in serum during acute infectious mononucleosis. *J. Infect. Dis.* 170: 436-439.
15. MUTIRANGURA, A. *et al.* 1998. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. *Clin. Cancer Res.* 4: 665-669.
16. SHOTELERSUK, K. *et al.* 2000. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. *Clin. Cancer Res.* 6: 1046-1051.
17. LO, Y.M.D. *et al.* 1999. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. *Cancer Res.* 59: 1188-1191.
18. PORNTHANAKASEM, W. *et al.* 2001. Human papillomavirus DNA in plasma of patients with cervical cancer. *BMC Cancer* 1: 2.
19. LO, Y.M.D. *et al.* 2001. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. *Cancer Res.* 61: 2351-2355.
20. CHEN, J.S. *et al.* 2001. Possible origin of extrachromosomal DNA from human lymphocytes treated *in vitro* with phytohemagglutinin. *Clin. Chem.* 47: 370.
21. LIEBER, M.R. 1998. Pathological and physiological double-strand breaks—roles in cancer, aging, and the immune system. *Am. J. Pathol.* 153: 1323-1332.
22. NIELSEN, J.L. *et al.* 1993. Evidence of gene amplification in the form of double minute chromosomes is frequently observed in lung-cancer. *Cancer Genet. Cytogenet.* 65: 120-124.
23. KRIPALANA-JOSHI, S. & H.Y. LAW. 1994. Identification of integrated Epstein-Barr virus in nasopharyngeal carcinoma using pulse field gel electrophoresis. *Int. J. Cancer* 56: 187-192.
24. JOAB, I. *et al.* 1991. Detection of anti-Epstein-Barr virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. *Int. J. Cancer* 48: 647-649.
25. ZENG, Y. *et al.* 1982. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou city, China. *Int. J. Cancer* 29: 139-141.
26. FENG, P. *et al.* 2000. Expression of Epstein-Barr lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis. *J. Gen. Virol.* 81: 2417-2423.
27. COCHET, C. *et al.* 1993. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. *Virology* 197: 358-365.
28. MARTEL-RENOIR, D. *et al.* 1995. Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. *J. Gen. Virol.* 76: 1401-1408.
29. SIDRANSKY, D. 2001. Nuclear genetic changes drive the progression of human cancers. *Clin. Chem.* 47: 361.
30. DUENAS, A. *et al.* 2001. DNA of human papillomavirus detected by PCR in plasma of cervical cancer patients: a potential marker of residual disease. *Clin. Chem.* 47: 364.

31. CAPONE, R.B. *et al.* 2000. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. *Clin. Cancer Res.* 6: 4171-4175.
32. LO, Y.M.D. *et al.* 1999. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. *Cancer Res.* 59: 5452-5455.
33. LO, Y.M.D. *et al.* 2000. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. *Cancer Res.* 60: 6878-6881.
34. SILVA, J.M. *et al.* 1999. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. *Cancer Res.* 59: 3251-3256.
35. YAMADA, T. *et al.* 1998. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. *Clin. Cancer Res.* 4: 1527-1532.
36. PAO, C.C. *et al.* 1997. Detection of human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis. *J. Clin. Oncol.* 15: 1008-1012.
37. GARCIA-OLMO, D. *et al.* 1999. Tumor DNA circulating in the plasma might play a role in metastasis: the hypothesis of the genomestasis. *Histopathology* 4: 1159-1164.
38. GALLAGHER, A. *et al.* 1999. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. *Int. J. Cancer* 84: 442-448.
39. TANGKIJVANICH, P. *et al.* 1999. Association of hepatitis viruses with hepatocellular carcinoma in Thailand. *J. Gastroenterol.* 34: 227-233.
40. WATANABE, T. 1997. HTLV-1-associated diseases. *Int. J. Hematol.* 66: 257-278.

Research article

Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study

Narisorn Kongruttanachok¹, Sairoong Sukdikul¹, Surachai Setavarin²,
Verachai Kerekhjanarong³, Pakpoom Supiyaphun³, Narin Voravud⁴,
Yong Poovorawan⁵ and Apiwat Mutirangura^{*1}

Address: ¹Genetics unit; Department of Anatomy,, ²National Cancer Institute, Bangkok, Thailand, ³Department of Otolaryngology,, ⁴Medical Oncology unit, and ⁵Viral Hepatitis Research Unit; Department of Medicine, Faculty of Medicine, Chulalongkorn University.

E-mail: Narisorn Kongruttanachok - ruttiwan@hotmail.com; Sairoong Sukdikul - sakdikul_s@hotmail.com;
Surachai Setavarin - bink506@hotmail.com; Verachai Kerekhjanarong - Virachaik@hotmail.com;
Pakpoom Supiyaphun - fmedpsp@md2.md.chula.ac.th; Narin Voravud - cu_mcdonco@hotmail.com;
Yong Poovorawan - pyong@chula.ac.th; Apiwat Mutirangura* - mapiwat@chula.ac.th

*Corresponding author

Published: 25 May 2001

Received: 16 February 2001

BMC Cancer 2001, 1:4

Accepted: 25 May 2001

This article is available from: <http://www.biomedcentral.com/1471-2407/1/4>

(c) 2001 Kongruttanachok et al, licensee BioMed Central Ltd.

Abstract

Background: Nasopharyngeal carcinoma (NPC) is a rare tumor in most parts of the world but occurs at relatively high frequency among people of Chinese descent. The cytochrome P450 2E1 enzyme (CYP2E1) is responsible for the metabolic activation of nitrosamines, and has been shown to be a susceptibility gene for NPC development in Taiwan [RR = 2.6; 95%CI = 1.2-5.7]. Since there has been only one report of this link, it was decided to investigate the susceptibility of CYP2E1 to NPC development in other populations. Therefore, the correlation between the RsaI polymorphism of this gene and NPC was studied in-patients including Thai and Chinese in Thailand. The present study comprised 217 cases diagnosed with NPC and 297 healthy controls.

Results: Similar to the result found in Taiwanese, a homozygous uncut genotype demonstrated a higher relative risk both when all cases were analyzed [RR = 2.19; 95%CI = 0.62-8.68] or individual racial groups, Thai [RR = 1.51; 95%CI = 0.08-90.06] or Chinese [RR = 1.99; 95%CI = 0.39-10.87]. The ethnicity-adjusted odds ratio is 2.39 with 95%CI, 0.72-7.89.

Conclusions: Though our finding was not statistically significant due to the moderate sample size of the study, similarity to the study in Taiwan with only a slight loss in precision was demonstrated. The higher RR found for the same genotype in distinct populations confirmed that CYP2E1 is one of several NPC susceptibility genes and that the RsaI minus variant is one mutation that affects phenotype.

Background

Nasopharyngeal carcinoma (NPC) is a rare tumor in most parts of the world, with annual age-standardized incidence rates typically below 1 per 100,000 people/year in both sexes [1]. The tumor occurs most often in

Southern Chinese who reside in Guangdong Province, at an incidence rate 30-50 per 100,000 people/year, in contrast with <1 per 100,000 people/year in white Europeans [2,3,4,5]. The disease also occurs at moderate frequencies (3-10 per 100,000 people/year) in several non-

Chinese ethnic groups such as Malay, Thai and Vietnamese [6]. Numerous factors, both environmental and genetic, have been associated with the risk of developing NPC. The environmental factors include infection with the Epstein-Barr virus (EBV), as well as frequent consumption of high levels of nitrosamine from preserved food such as salted fish [7,8,9]. In addition, host factors also play a major role in NPC development. Unique alleles of the human leukocyte antigen (HLA) and cytochrome P450 2E1 (*CYP2E1*) have been shown to be associated with high relative risk in several Asian ethnic groups, including the Chinese in Taiwan [10,11,12].

CYP2E1, an enzyme involved in the metabolic activation of procarcinogens into reactive intermediates capable of forming adducts and damaging DNA, is believed to play an essential role in chemical carcinogenesis [13,14]. Nitrosamine is a substrate of *CYP2E1*. It is believed that nitrosamine, once activated can lead to the development of numerous cancers [15]. Studies have also demonstrated that *CYP2E1* is expressed in the nasal epithelium of human [16]. Evidence from previous epidemiological studies has suggested that salted fish is a food preferred by Chinese people and contains nitrosamines and nitrosamine precursors [9]. Therefore, *CYP2E1* is believed to render the nasopharyngeal epithelium susceptible to NPC development. A previous study in Taiwan employed a PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) assay using the restriction enzyme *RsaI* in order to compare wild-type (+/+) and variant forms (-/-) of the *CYP2E1* gene between NPC patients and the general population [10,11]. The variant form of contains *CYP2E1* polymorphic mutations in the distal 5'-flanking region of the gene, causing a marked difference in its transcriptional activity, as shown by CAT (chloramphenicol acetyltransferase) [17]. The Taiwanese association study showed that individuals homozygous for the variant allele (-/-) were at an increased risk for NPC development (relative risk [RR] = 2.6; 95% confidence interval [CI] = 1.2-5.7) [11]. There are many Chinese people who have immigrated and permanently lived in Thailand for 2 to 3 generations, resulting in a mixed population of Thai and Chinese people. From clinical observation, we had observed at least one-third of NPC patients were Chinese in origin. Since the susceptibility of *CYP2E1* gene to develop NPC had only been reported from Chinese people in Taiwan, it was decided to investigate whether this allele played the same role in other populations. Therefore, we studied the correlation of the polymorphism of the *CYP2E1* gene with NPC in Thai and Chinese populations in Thailand.

Materials and Methods

Sample collection

Blood samples were obtained by venipuncture from 217 NPC patients at Chulalongkorn Hospital and 297 healthy blood donors. All subjects were interviewed and separated into two groups, Thai and Chinese, based on their grandparents' ethnic origin. When their ancestors, including their great grandparents, originated from China, the patients were considered Chinese. When their ancestors originated from Thailand, the patients were considered Thai. There were 99 Thai and 98 Chinese in the control group. The NPC patient group included 132 Thai and 56 Chinese.

PCR-RFLP analysis

Genomic DNA (0.1 µg) extracted from leukocytes was used for each PCR analysis. The amplification was performed with primers as described previously by Hayashi et al. The total reaction volume of 50 µl consisted of 20 µM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl₂, 125 µM deoxynucleoside triphosphate, 0.2 µM primers, 4 U Taq DNA polymerase (Gibco), and 0.2 µg of template DNA. The PCR conditions were 40 cycles at 92°C for 1 minute, 60°C for 1 minute and 72 for 2 minutes in a Perkin-Elmer/DNA thermal Cycle 480. Genotype of *CYP2E1* gene were determined by RFLP analysis. Twenty microliters of PCR products were digested with 10 U *RsaI* restriction enzyme (New England Biolabs) overnight at 37°C. The restricted products were analyzed by electrophoresis on 2% agarose gel. Bands were visualized with an ultraviolet transilluminator after ethidium bromide staining.

Statistical Analysis

The relative risk (RR) was estimated by the odds ratio method, to determine the correlation between genotype of the *CYP2E1* gene and NPC development. In addition, the RR was used to estimate the association of the pattern of genetic inheritance of the *CYP2E1* gene and NPC phenotype. The 95% confidence interval (CI) was computed to determine the statistical significance of the findings. The RR and 95%CI was calculated by using Exact method from Epi info version6 program.

Results

In the present study, we investigated the correlation between the polymorphism of the *CYP2E1* gene and NPC on a total of 217 patients and 297 controls. The diagnosis of NPC was confirmed histologically and by the presence of EBV DNA in the tumor. PCR-RFLP analysis was used to evaluate *RsaI* polymorphism in the *CYP2E1* gene (fig 1). The distribution of alleles in all, Thai and Chinese were found to be in Hardy-Weinberg equilibrium. The calculated frequencies of heterozygous using $2x(+/-)^{1/2} \times x(-/-)^{1/2}$ were 0.32, 0.26, 0.42 from all, Thai, and Chi-




Figure 1
PCR-RFLP assay to detect the polymorphism of the *CYP2E1* gene by *RsaI* enzyme digesting the 410 bp PCR product into 360 bp and 50 bp fragments. Lane 1, homozygous variant (-/-); Lane 2, heterozygous (+/-); Lane 3, homozygous wild type (+/+).

nese NPC patients, and 0.32, 0.26 and 0.42 from all, Thai and Chinese control, respectively. These numbers are similar to actual frequencies of heterozygous from all groups, 0.32, 0.28, 0.42, 0.35, 0.28, 0.52 from all, Thai and Chinese patients and all, Thai and Chinese control, respectively. We found the relative risk of the variant form (-/-) of the *CYP2E1* gene at a high risk [RR = 2.19]. However, this result had no statistical significance [95%CI = 0.62-8.68]. To evaluate whether the lack of significance of the trend was due to a mixed genetic background, both patients and controls were analyzed according to the origins of their ancestors (Thai or Chinese). A slightly increased risk of the variant form (-/-) of the *CYP2E1* gene could be demonstrated in both the Thai and Chinese sample groups [RR = 1.51; 95%CI = 0.08-90.06, RR = 1.99; 95%CI = 0.39-10.87, respectively]. Nevertheless, no statistical significance could be established. The estimated crude odds ratio lies outside of two ethnicity-specific odds ratios for Thai and Chinese indicates ethnicity is a confounder in this genotype-phenotype association. Odds ratio for the combined group of subjects with ethnicity information can be calculated with adjustment for ethnicity. The ethnicity-adjusted odds ratio (-/- vs +/-) is 1.86 (95%CI = 0.55-6.31). A similar adjustment using the whole sample of three groups, Thai, Chinese, and ethnicity unspecified showed an odd ratio of 2.39, with only a slight loss in precision (95%CI = 0.72-7.89). This is close

er to the odds ratio of 2.6 from the study in Taiwan. Furthermore, Thai-Taiwanese comparison was done quantitatively by testing $H_0: OR(\text{Thai}) = OR(\text{Taiwan})$. Using Mantel-Haenszel test for odds ratio homogeneity, the p-value was 0.81. Thus there is no statistical difference for the role of *CYP2E1* on NPC development between these two populations.

In this study, we further analyzed the association of the pattern of genetic inheritance of *CYP2E1* gene and NPC phenotype by calculating the relative risk if the genotype were either autosomal dominant (AD) or autosomal recessive (AR). In autosomal dominance, the contribution of a single variant allele would show a higher RR. Thus the RR for the combination of the heterozygous (+/-) and the variant form (-/-) compared with wild type (+/+) were computed. There was no association between AD heredity and NPC risk in the total, Thai, and Chinese sample groups [RR = 1.00; 95%CI = 0.68-1.47, RR = 1.01; 95%CI = 0.55-1.87, RR = 0.84; 95%CI = 0.41-1.71, respectively] (Table 2). By contrast, AR inheritance requires an abnormality in both alleles of the *CYP2E1* gene. The RR were calculated by comparison between the wild type (+/+), the heterozygous (+/-) or the combination of the wild type and heterozygous (+/+ and +/-) and the variant form (-/-). A higher RR value in all comparisons was shown for AR heredity in all sample groups (Table

3). However, these results showed no statistical significance for either the AD or AR pattern.

Table 1: Frequency distribution and relative risks associated with genotype variants of CYP2E1 detected RFLP using RsaI

CYP2E1	Frequency		RR	95%CI
	Cases	Controls		
Total	217*	297		
+/+	138	189	1.00	
+/-	71	103	0.94	0.64 - 1.39
-/-	8	5	2.19	0.62 - 8.68
Thai	132	99		
+/+	93	70	1.00	
+/-	37	28	0.99	0.54 - 1.86
-/-	2	1	1.51	0.08 - 90.06
Chinese	56	98		
+/+	27	43	1.00	
+/-	24	51	0.75	0.36 - 1.57
-/-	5	4	1.99	0.39 - 10.87

* 29 cases lack precise information regarding ethnicity +, The allele could be digested with *RsaI* enzyme -, The allele could not be digested with *RsaI* enzyme

Table 2: Correlation between Autosomal Dominant (AD) pattern of genetic CYP2E1 gene and NPC phenotype

CYP2E1	Frequency		RR (AD)	95%CI
	Cases	Controls		
Total				
+/+	138	189	1.00	
+/- and -/-	79	108	1.00	0.68 - 1.47
Thai				
+/+	93	70	1.00	
+/- and -/-	39	29	1.01	0.55 - 1.87
Chinese				
+/+	27	43	1.00	
+/- and -/-	29	55	0.84	0.41 - 1.71

+, The allele could be digested with *RsaI* enzyme -, The allele could not be digested with *RsaI* enzyme

Table 3: Correlation between Autosomal Recessive (AR) pattern of genetic CYP2E1 gene and NPC phenotype

CYP2E1	Frequency		RR (AR)	95%CI
	Cases	Controls		
Total				
+/+	138	189	1.00	
-/-	8	5	2.19	0.62 - 8.68
+/+	71	103	1.00	
-/-	8	5	2.32	0.64 - 9.36
+/+ and +/-	209	292	1.00	
-/-	8	5	2.24	0.63 - 8.80
Thai				
+/+	93	70	1.00	
-/-	2	1	1.51	0.08 - 90.06
+/+	37	28	1.00	
-/-	2	1	1.51	0.07 - 92.44
+/+ and +/-	130	98	1.00	
-/-	2	1	1.51	0.08 - 89.84
Chinese				
+/+	27	43	1.00	
-/-	5	4	1.99	0.39 - 10.87
+/+	24	51	1.00	
-/-	5	4	2.66	0.51 - 14.48
+/+ and +/-	51	94	1.00	
-/-	5	4	2.30	0.47 - 12.08

+, The allele could be digested with *RsaI* enzyme -, The allele could not be digested with *RsaI* enzyme

Discussion

We have shown an increased risk of developing NPC associated with the homozygous variant form of the *CYP2E1* gene. This higher RR was demonstrated in both the Thai and Chinese populations in Thailand. This finding was similar to the result reported from Taiwan. However, these results were marginal statistical significance, which may well be due to the small sample size employed in the present study. Thus the *CYP2E1* gene appears to be a susceptibility gene for NPC development regardless of the patient's genetic background. Patients of both Thai and Chinese ethnic origin revealed a higher relative risk from the same allele, despite their distinct ancestry. Thus it is more likely that the *RsaI* negative allele affects the phenotype directly rather than being a consequence of linkage disequilibrium from another mutation or gene. This confirms the previous finding that the polymorphic *RsaI* site was essential for a marked difference in transcriptional activities [17]. A higher level of expression in the variant form would result in larger amounts of pro-carcinogens being changed into carcinogens, that then produce DNA damage. The affect of the distinct expression level of a metabolic gene should be reduced if the

person with abnormal genotype is not exposed to the substrate. For example, Phenylketonuria (PKU) patients would not demonstrate mental retardation if they were prevented completely from exposure to tyrosine [18]. In other words, a mutation can not cause the phenotype without interaction from environmental factors. Regarding NPC development, the role of *CYP2E1* variant may be varied upon the amount of consumed salted fish and/or preserved foods that contain nitrosamine and nitrosamine precursors.

Conclusion

Result of the reported crude odds ratio is 2.19 [95%CI = 0.62-8.68]. If the result is adjusted odds ratio, it will be 2.39 [95%CI = 0.72-7.89], which is closer to the Taiwanese odds ratio of 2.6, with only a slight loss in precision. Thus, this study confirmed a previous study in Taiwan that *CYP2E1* appears to be one of a number of NPC susceptibility genes and the *RsaI* minus variant is not just a polymorphism but directly influences the development of the phenotype.

Acknowledgments

We deeply indebted to the staff of the Department of Otolaryngology and the Radiotherapy Section, Department of Radiology, Chulalongkorn Hospital and National Blood Center for the recruitment of patients and collection of materials. This work was supported by Molecular Biology Project, Faculty of Medicine, Chulalongkorn University and the Thailand research Fund.

Competing interests

None declared

References

- Parkin DM, Muir CS: Cancer Incidence in Five Continents: Comparability and quality of data. *IARC Sci Publ* 1992, 120:45-173
- Simons MJ, Wee GB, Singh D, Dharmalingham S, Yong NK, Chau JC, Ho JH, Day NE, De The G: Immunogenetic aspects of nasopharyngeal carcinoma. V. Confirmation of a Chinese-related HLA profile (A2, Singapore 2) associated with an increased risk in Chinese for nasopharyngeal carcinoma. *Natl Cancer Inst Monogr* 1977, 47:147-51
- Cui HY: Apparent correlation between nasopharyngeal carcinoma and HLA phenotype. *Chung Hua Chung Liu Tsa Chih* 1982, 4(4):249-53
- Chan SH: Aetiology of nasopharyngeal carcinoma. *Ann Acad Med Singapore* 1990, 19(2):201-7
- Zhu XN, Chen R, Kong FH, Lju W: Human leukocyte antigens - A, -B, -C, and -DR and nasopharyngeal carcinoma in northern China. *Ann Otol Rhinol Laryngol* 1990, 99(4 Pt 1):286-7
- Muir CS: Nasopharyngeal carcinoma in non-Chinese populations with special reference to south-east Asia and Africa. *Int J Cancer* 1971, 15:351-63
- Choi PH, Suen MW, Huang DP, Lo KW, Lee JC: Nasopharyngeal carcinoma: genetic changes, Epstein-Barr virus infection, or both. A clinical and molecular study of 36 patients. *Cancer* 1993, 15:2873-8
- Hildesheim A, Levine PH: Etiology of nasopharyngeal carcinoma: a review. *Epidemiol* 1993, 15(2):466-85
- Zheng YM, Tuppin P, Hubert A, Jeannel D, Pan YJ, Zeng Y, de The G: Environmental and dietary risk factors for nasopharyngeal carcinoma: a case-control study in Zangwu County, Guangxi, China. *Br J Cancer* 1994, 69(3):508-14
- Hildesheim A, Chen CJ, Caporaso NE, Cheng YJ, Hoover RN, Hsu MM, Levine PH, Chen IH, Chen JY, Yang CS, et al: Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan. *Cancer Epidemiol Biomarkers Prev* 1995, 4(6):607-10
- Hildesheim A, Anderson LM, Chen CJ, Cheng YJ, Brinton LA, Daly AK, Reed CD, Chen IH, Caporaso NE, Hsu MM, et al: CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. *J Natl Cancer Inst* 1997, 89(16):1207-12
- Nebert DW: Role of genetics and drug metabolism in human cancer risk. *Mutat Res* 1991, 247(2):267-81
- Poulsen HE, Loft S, Wassermann K: Cancer risk related to genetic polymorphisms in carcinogen metabolism and DNA repair. *Pharmacol Toxicol* 1993, 72 Suppl 1:93-103
- Bartsch H, Montesano R: Relevance of nitrosamines to human cancer. *Carcinogenesis* 1984, 5(11):1381-93
- Gervasi PG, Longo V, Naldi F, Panattoni G, Ursino FX: enobiotic-metabolizing enzymes in human respiratory nasal mucosa. *Biochem Pharmacol* 1991, 15:41(2):177-84
- Poirier S, Bouvier G, Malaveille C, Ohshima H, Shao YM, Hubert A, Zeng Y, de The G, Bartsch H: Volatile nitrosamine levels and genotoxicity of food samples from high-risk areas for nasopharyngeal carcinoma before and after nitrosation. *Int J Cancer* 1989, 5:44(6):1088-94
- Hayashi S, Watanabe J, Kawajiri K: Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P45011E1 gene. *J Biochem (Tokyo)* 1991, 110(4):559-65
- Bruce RK: Human Genetics: A problem-Based Approach. Massachusetts: Blackwell Science 1999

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/content/backmatter/1471-2407-1-4-b1.pdf>

Publish with **BioMedcentral** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright



BioMedcentral

Submit your manuscript here:
<http://www.biomedcentral.com/manuscript/>

editorial@biomedcentral.com

ยีน FERB11 (MIC) กับการเกิดโรคมะเร็งโพรงหลังจมูก

วิชัย พรชนเกษม
นริศร คงรัตนโชค
สายรุ้ง ศักดิ์กุล
ชาญวิทย์ สีสายวัฒน์
สุรัชย์ สีตะวาริน
วีระชัย ศิริกาญจนะรงค์
ภาณุภูมิ สุปิยะพันธุ์
นรินทร์ วรวิมล
ยง ภู่วรรณ
อภิวัฒน์ มุทิตรางกูร

PERB11 (MIC) as a possible susceptibility gene for nasopharyngeal cancer development

Wichai Pornthanakasem* Narisorn Kongruttanachok**

Sairoong Sakdikul** Chanvit Leelayuwat***

Surachai Setavarin**** Verachai Kerekhajanarong*****

Pakpoom Supiyaphan***** Narin Voravud****

Yong Poovorawan***** Apiwat Mutirangura**

Pornthanakasem W, Kongruttanachok N, Sakdikul S, Leelayuwat C, Setavarin S, Kerekhajanarong V, Supiyaphan P, Voravud N, Poovorawan Y, Mutirangura A. *PERB11 (MIC) as a possible susceptibility gene for nasopharyngeal cancer development. Chula Med J 2001 Mar; 45(3): 207 - 13*

Background : *There have been many studies indicating that a gene located near HLA A2 and HLA B46 is a tumor susceptibility gene involved in nasopharyngeal cancer (NPC) development. PERB11 (MIC) is a candidate gene since it is linked to HLA B.*

Objective : *To investigate the association between PERB11 (MIC) and the probability of having NPC.*

Materials and Methods : *The frequencies of six alleles from a triplet repeat polymorphism of the transmembrane region of MICA (PERB11.1) were analyzed by PCR from 300 healthy blood donors' and 171 NPC patients' DNA samples. The relative risk was estimated by odds ratio to determine the allele association with NPC patients in comparison with normal controls.*

* Department of Microbiology, Faculty of Medicine, Chulalongkorn University

** Department of Anatomy, Faculty of Medicine, Chulalongkorn University

*** Department of Clinical Immunology CMII-KKU Institutional Cooperative Centre, Faculty of Associated Medical Sciences, Khon Kaen University

**** Department of Medicine, Faculty of Medicine, Chulalongkorn University

***** Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University

***** Department of Pediatrics, Faculty of Medicine, Chulalongkorn University -

- Result** : *The frequency of the A6 allele, but not others, was increased in the patient group, as compared with the control group (RR = 1.6, $P < 0.05$, OR = 1.60, 95 % CI = 0.98-2.63).*
- Conclusion** : *One particular allele (A6) of the PERB11 (MIC) gene presents at a higher frequency in NPC patients than in controls. This suggests a possible association of NPC development with the PERB11 gene.*
- Key words** : *PERB11 (MIC) gene, Polymorphism, Nasopharyngeal cancer.*

Reprint request: Mutirangura A, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Received for publication. November 5, 2000.

วิชัย พรธนเกษม, นริศร คงรัตนโชค, สายรุ้ง ศักติกุล, ชาญวิทย์ สีสายวัฒน์, สุรัชย์ สิตะวาริน, วีระชัย ศิริกาญจนะรงค์, ภาควณิ สุปิยพันธ์, นรินทร์ วรวิทย์, ยง ภู่วรรณ, อภิวัฒน์ มุทิตาภิบาล.
ยีน PERB11(MIC) กับการเกิดโรคมะเร็งโพรงหลังจมูก. จุฬาลงกรณ์เวชสาร 2544 มี.ค; 45(3):
207 - 13

- ปัญหาของการทำวิจัย :** มีการศึกษาพบว่ายีนที่อยู่บริเวณ HLA A2 และ HLA B46 เป็นยีนที่ส่งเสริมให้เกิดมะเร็งชนิดนี้ เนื่องจากยีน PERB11 (MIC) เป็นยีนที่อยู่ใกล้กันกับยีน HLA B ดังนั้น PERB11 (MIC) อาจจะเกี่ยวข้องกับการเกิดโรคมะเร็งโพรงหลังจมูก
- วัตถุประสงค์ :** เพื่อศึกษาหาความสัมพันธ์ระหว่างยีน PERB11 (MIC) กับการเกิดโรคมะเร็งโพรงหลังจมูก
- วัสดุและวิธีการวิจัย :** คณะผู้วิจัยได้ทำการศึกษาความสัมพันธ์ระหว่างยีน PERB11 (MIC) กับการเกิดโรคมะเร็งโพรงหลังจมูกโดยเปรียบเทียบระหว่างดีเอ็นเอจากเลือดคนปกติ 300 ราย และ 171 รายจากคนผู้ป่วยที่ได้รับการตรวจวินิจฉัยว่าเป็นโรคมะเร็งโพรงหลังจมูกโดยหาความสัมพันธ์ระหว่างความถี่ของอัลลีลทั้งหมดของ triplet repeats ในส่วนของยีนที่สร้างโปรตีนอยู่ในเยื่อเซลล์ของยีน PERB11 (MIC) ในกลุ่มของผู้ป่วยกับคนปกติโดยดูถึง
- ผลการศึกษา :** พบว่าความถี่ของยีนเฉพาะอัลลีล A6 เพิ่มขึ้นในกลุ่มของผู้ป่วยเมื่อเปรียบเทียบกับกลุ่มคนปกติ ($R.R.=1.6$, $P < 0.05$, $OR = 1.60$, $95\% CI = 0.98-2.63$) แต่ไม่พบการเพิ่มขึ้นอย่างมีนัยสำคัญในอัลลีลอื่น ๆ ของยีน PERB11 (MIC)
- สรุป :** ข้อมูลของคณะผู้วิจัยพบว่ามีความถี่ของอัลลีล A6 เพิ่มขึ้นในกลุ่มผู้ป่วยที่เป็นโรคมะเร็งโพรงหลังจมูกเมื่อเปรียบเทียบกับกลุ่มคนปกติ แสดงให้เห็นถึงความเป็นไปได้ของความสัมพันธ์ระหว่างการเกิดโรคมะเร็งโพรงหลังจมูกกับยีน PERB11 (MIC)

The etiology of nasopharyngeal carcinoma (NPC) has opened an interesting field of study concerning the interplay between genetic and environmental factors combined with Epstein – Barr virus (EBV) infection. NPC is rare among Caucasians, with incidence rates below 1 per 100,000 persons/year. Among Chinese, with a high incidence rate (30 - 50 per 100,000/year) and Southeast Asians with an intermediate rate (3 - 10 per 100,000 people/year), the possibility of a genetic contribution becomes apparent. There have been many reports indicating various human leukocyte antigen (HLA) alleles are associated with NPC. The link between HLA and NPC was first reported in Singapore⁽¹⁾ and this finding has subsequently been confirmed in several countries in Asia.⁽²⁾ All have demonstrated the association with HLA-A2 and HLA-B46 (relative risk = 2.35). However, HLA-A2 subtyping studies have shown that it is unlikely to play a role in the EBV clearance hypothesis. In addition, in a causative association the risk would increase if both HLA-A2 and B46 were inherited on the same chromosome, i.e. haplotype. In contrast, this HLA haplotype in non-Chinese patients is not associated with NPC. These data suggest that HLA is not the susceptibility gene *per se*, but the NPC susceptibility gene locus is most likely to reside within the HLA region.

PERB11 (MIC), a major histocompatibility complex (MHC) class I chain-related gene, is located in the HLA region. *PERB11.1 (MICA)*, an expressed *PERB11*, has recently been identified to be located near the HLA-B locus^(3,4) and displays 6 distinct alleles of microsatellite polymorphism in the transmembrane (TM) region.^(5,6) *MICA* is frequently expressed in epithelial tumors. Upon interaction between MICA

and its receptor NKG2D, diverse innate anti-tumor NK cell and antigen-specific T-cell responses are triggered.⁽⁷⁾ Therefore, *PERB11 (MIC)* is a candidate tumor susceptibility gene.

In this study, we have investigated the correlation between short tandem repeat polymorphisms in the TM of *PERB11.1 (MICA)* and NPC development in a total of 171 cases diagnosed with NPC and 300 controls. The hypothesis was that if one of the alleles was significantly increased in the patients, as compared with the control group, the *PERB11 (MIC)* gene might be a NPC susceptibility gene.

Method

Samples and DNA extraction

Blood samples were obtained by venipuncture from 300 healthy blood donors (Thai Red-Cross Society) and 171 NPC patients (Chulalongkorn Hospital and National Cancer Institute). The diagnosis had been confirmed histologically and by the presence of EBV DNA in the tumors. DNA was extracted from blood leukocytes by methods previously described.⁽⁸⁾

PCR

For analysis of the microsatellite repeat polymorphism in the TM region of the *MICA* gene, PCR primers flanking the TM region were used (*MICA5F*, 5'-CCTTTTTTTCAGGGAAAGTGC-3'; *MICA5R*, 5'-CCTTACCATCTCCAGAAACTGC-3').⁽⁵⁾ The PCR reactions were performed in a total volume of 10 µl using 50 ng of genomic DNA, 200 µM each dNTP, 10 µM Tris-HCl (pH 8.4), 50 mM potassium chloride, 2.5 mM magnesium chloride, 0.5 units of *Thermus aquaticus* DNA polymerase (Perkin Elmer Cetus) and

0.1 μ M of each primer. One of each primer pair was end labelled at 37°C for 1-2 h in a total volume of 10 μ l containing 10 μ M primer, 0.025 mCi [γ - 32 P] ATP (Amersham Pharmacia Biotech) at 3000 Ci mmol⁻¹, 10 μ M magnesium chloride, 5 mM DTT, 70 mM Tris-HCl (pH 7.6) and 10 units of T4 polynucleotide kinase (New England Biolabs). Without further separating of the unincorporated nucleotides, the kinase reaction was added to the PCR buffer mix. The PCR amplifications were performed as follows: initial denaturation at 94°C for 5 min, followed by 25 cycles of denaturation at 95°C for 1 min, annealing at 55°C for 1 min, extension at 72°C for 2 min and a final extension at 72°C for 7 min.

Two microlitres of each reaction were mixed with 1 μ l of formamide-loading buffer, heated at 95°C for 2 min, put on ice for 30 s and then loaded onto 6 % polyacrylamide/7 M urea gel. DNA fragments were size fractionated at 70 W until the tracking dye had covered the appropriate distance of the gel. After electrophoresis, the wet gel was transferred to filter

paper (Whatman), wrapped with Saran wrap and exposed to a phosphorus screen; the bands were visualized on PhosphorImager using ImageQuaNT software (Molecular Dynamics).

Statistical Analysis

Gene frequencies were estimated by direct counting. The significance of the distribution of alleles between NPC patients and normal controls were tested by chi-square (χ^2) method with continuity correction and Fisher's extra probability test (P value test).⁽⁹⁾ Comparison between two groups was made with a 95 % confidence interval to estimate statistical significance.

Result and Discussion

To address the possibility that *MICA* is a susceptibility gene for NPC development, triplet repeat polymorphisms in the TM region of *PERB11.1 (MICA)* were investigated in 171 cases diagnosed with NPC and 300 healthy blood donors as a control (Fig 1).




Figure 1. Microsatellite analysis of PCR-amplified products of triplet repeat polymorphism in the TM region of the *PERB11.1 (MICA)* gene. Cases 1-14: nasopharyngeal cancer patients. M, molecular marker.

PERB11 displays 6 distinct alleles of microsatellite polymorphism at the TM region. The frequency of A6 allele was significantly increased in the patient group, as compared with the control group (R.R. = 1.6, $P < 0.05$, O.R. = 1.60, 95 % CI = 0.98 - 2.63) (Table 1) but none of the other alleles showed any significant association. These data suggest a possible important role for this allele in the development of NPC. Interestingly, A6 is the same allele found to be associated with Behçet disease in the Japanese population.⁴⁸

In conclusion, we have found that one particular allele (A6) of the microsatellite is present at a higher frequency in NPC patients than in controls. Yet, since the 95 % CI contains the nominator 1 the OR value does not achieve significance. This may well be due to the small sample size employed in the present study. Since the TM polymorphism is not well correlated with polymorphisms of the extracellular domains,¹⁹ it is essential to further evaluate this polymorphism to establish the relevance of this gene family in NPC development.

Acknowledgment

We express our gratitude to all personal in the department of Otolaryngology and Radiotherapy section, Department of Radiology, Faculty of Medicine, Chulalongkorn University and the National Blood Center for recruitment of patients and collection of materials. This study was supported by the Molecular Biology Project, Faculty of Medicine, Chulalongkorn University and the Thailand Research Fund.

References

1. Simons MJ, Wee GB, Cham SH, Shammugaraman K. Probable identification of a second locus antigen associated with a high risk of nasopharyngeal carcinoma. *Lancet* 1975 Jan 18; 1(7899): 142 - 3.
2. Ren EC, Chan SH. Human leucocyte antigens and nasopharyngeal carcinoma. *Clin Sci (Colch)* 1996 Sep; 91(3): 256 - 8.
3. Leelayuwat C, Townsend DC, Degli-Esposti MA, Abraham LJ, Dawkins RL. A new polymorphic

Table 1. Gene frequencies of the microsatellite polymorphism in the TM region (exon 5) of the *PERB11.1* (MICA) gene in nasopharyngeal carcinoma

Microsatellite allele	Amplified product (bp)	Control (n = 600)	Patient (n = 342)	P value	R.R.	95% CI
A4	179	87	40			
A5	182	220	129			
A5.1	183	138	70			
A6	185	41	36	0.046	1.60	0.98 - 2.63
A9	194	114	67			

and multicopy MHC gene family related to nonmammalian class I. Immunogenetics 1994; 40(5): 339 - 51

4. Bahram S, Bresnahan M, Geraghty D, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994 Jul 5; 91(14): 6259 - 63
5. Mizuki N, Ota M, Ohno S, Ando H, Katsuyama Y, Yamazaki M, Watanabe K, Goto K. Triplet repeat polymorphism in the transmembrane region of the MICA gene: A strong association of six GCT repetitions with Behçet disease. Proc Natl Acad Sci USA 1997 Feb 18; 94(4): 1298 - 303
6. Perez-Rodriguez M, Corell A, Arguello JR, Cox ST, McWhinnic A, Marsh SG, Madrigal JA. A new MICA allele with ten alanine residues in the exon 5 microsatellite. Tissue Antigens 2000 Feb;

55(2): 162 - 5

7. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999 Jul 30; 285(5428): 727 - 9
8. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual. 2nd ed. New York: Cold Spring Harbor, Cold Spring Harbor Laboratory, 1989 : 9.16 - 9.23
9. Thompson GA. A review of theoretical aspects of HLA and disease associations. Theor Popul Biol. 1981 Oct; 20(2): 168 - 208
10. Cattley SK, Longman N, Gaudieri S, Dawkins RL, Leelayuwat C. Phylogenetic analysis of primate PERB11(MIC) sequences suggests that the representation of the gene family differs in different primates. Comparison of MIC (PERB11) and C4. Eur J Immunogenet 1999 Apr - Jun; 26(2-3): 233 - 8

Case Report

Astroblastoma: Report of a case with microsatellite analysis

Shanop Shuangshoti,¹ Woranart Mitphraphan,² Somruetai Kanvisetsri,¹ Lisa Griffiths,² Yot Navalitloha,³ Wichai Pornthanakasem⁴ and Apiwat Mutirangura⁴

Departments of ¹Pathology, ²Radiology, ³Surgery and ⁴Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand and ⁵Department of Neuropathology, Royal Perth Hospital, Perth, Western Australia

A 5-year-old girl who developed progressive headache, vomiting, and left hemiparesis was found to have a cystic tumor with an enhanced mural nodule in the right frontoparietal region on a computed tomography examination. The lesion was histologically and ultrastructurally verified as an astroblastoma, an uncommon neuroepithelial tumor of uncertain origin. Molecular analysis using 17 microsatellite markers on chromosomes 9, 10, 11, 17, 19, and 22 showed loss of heterozygosity at the D19S412 locus on the long arm of chromosome 19. This observation suggests that there is a tumor suppressor gene in this chromosomal region, which plays a role in the pathogenesis of astroblastoma.

Key words: astroblastoma, glioma, loss of heterozygosity, tumor suppressor gene.

INTRODUCTION

Bailey and Busy originally described astroblastomas in 1930 and considered their prognosis to be intermediate between that of astrocytoma and glioblastoma.¹ Exact epidemiological data of astroblastomas are not available but, in general, they are uncommon and most frequently affect young individuals, usually as circumscribed supratentorial tumors.^{1,2}

Because of their rarity, information regarding the genetics of astroblastomas is scant. Cytologic analysis of one case demonstrated an abnormal hypodiploid karyotype with 45 chromosomes and monosomies of chromosomes 10, 21, and 22 and two additional marker chromosomes in all cells studied.³ Molecular analysis of

another example disclosed allelic loss on chromosomes 4p, 6p, 13q, 17p, 17q, 22q and Y.⁴ One of the present paper is to report a case of astroblastoma in which we have investigated the loss of tumor suppressor gene in the pathogenesis by using microsatellite heterozygosity (LOH) on the chromosomes 9, 10, 11, 17, 19, and 22, which occurs commonly in human cancer.

CLINICAL SUMMARY

A 5-year-old girl presented with a 2-month history of progressive headache and vomiting. Weakness of left extremities was noticed 1 month prior to admission. Neurological examination revealed left hemiparesis, bilateral papilledema. A contrast-enhanced computed tomography (CT) scan of the brain (Fig. 1) showed a well-demarcated cystic mass measuring 6.5 × 4.2 cm, a hyperdense mural nodule in the right frontoparietal region. The lesion involved the right basal ganglia and extended to the right posterior limb of internal capsule as well as into the deep white matter of the right lobe. The right lateral ventricle was compressed and displaced. There was evidence of right uncal and tentorial herniations.

Intraoperatively, the tumor was totally removed. A yellow fluid was found in the cystic component. The postoperative course was uneventful. The patient received megavoltage radiation therapy.

METHODS

Sections from formalin-fixed paraffin-embedded tissue were histologically examined with hematoxylin and eosin. Immunohistochemical studies were performed using the following antibodies: glial fibrillary acidic protein (GFAP), S-100 protein, vimentin, epithelial membrane antigen (EMA) and neurofilament protein (NF). Details of antibodies used and results are given in Table 1. Elect

Correspondence: Shanop Shuangshoti, MD, Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Received 16 December 1999; revised and accepted 20 March 2000.

Table 1 Antibodies used in the immunohistochemical study of astroblastoma

Antibodies	Species	Clonality	Source	Dilution	Result
Anti-GFAP	Rabbit	Polyclonal	Dako	1:1000	+
Anti-S-100 protein	Rabbit	Polyclonal	Dako	1:400	+
Anti-vimentin	Mouse	Monoclonal	Dako	1:200	+
Anti-EMA	Mouse	Monoclonal	Dako	1:50	-
Anti-NF	Mouse	Monoclonal	Dakos	1:100	-

GFAP, glial fibrillary acidic protein; EMA, epithelial membrane antigen; NF, neurofilament; Dako, Japan



Fig. 1 An axial postcontrast computed tomography scan showing a well-circumscribed cystic mass with a moderately enhanced mural nodule in the right frontoparietal region.

microdissection was carried out using representative tissue extracted from a paraffin block.

LOH was determined using 17 microsatellite polymorphic markers on chromosomes 9 (D9S1748: 9p21, RPS6: 9p21, IFNA: 9p22), 10 (D10S196: 10q11.2, D10S178: 10pter-10qter, D10S249: 10pter-10qter), 11 (D11S554: 11p12-11p11.2, WT1: 11p13), 17 (D17S1176: 17p13.1, TP53: 17p31.1, D17S1876: 17pter-17qter), 19 (D19S47: 19q13.1, ERCC1: 19q13.2, D19S412: 19q13.3) and 22 (D22S281: 22q12.2-12.3, D22S284: 22q13.1-13.2, D22S282: 22q13.2-13.3). Information regarding the cytogenetic localization of the markers was obtained from the Genome Data Base.

Before microsatellite analyses, tumor DNA extracted from 20 paraffin sections of 5 μ m thickness from a tissue area of 2.0 \times 1.5 cm was amplified by degenerated oligonucleotide-primed polymerase chain reaction (DOP-PCR) in a total volume of 50 μ L as previously described.⁸ One strand of each primer pair was end-labeled as described elsewhere.⁹ The PCR reactions were performed in a total volume of 10 μ L consisting of 200 μ mol/L deoxyribonucleoside triphosphate, 10 mmol/L tris-HCL

(pH 8.4), 50 mmol/L KCL, 1.5 mmol/L MgCL, 0.5 U *Thermus aquaticus* DNA polymerase (Perkin Elmer Corp., Norwalk, CT, USA), primer concentrations between 0.1 and 0.5 μ mol/L each, and 50 ng of genomic DNA (from both leukocyte extraction and DOP-PCR extracted paraffin-embedded tissue).

Several PCR reactions have been optimized for this primer set as follows: an initial denaturation step at 95°C for 4 min, followed by 40 cycles of denaturation at 95°C for 1 min, with 1 min annealing at 55°C, extension at 72°C for 2 min, and a final extension at 72°C for 7 min.

Aliquots (2 μ L) of each reaction were mixed with 1 μ L of formamide-loading buffer, heated at 95°C for 2 min, chilled on ice for 30 s, and then loaded onto a 10% polyacrylamide 7 mol/L urea gel. DNA fragments were size-fractionated at 70 W-unit until the tracking dye had reached the appropriate distance on the gel. After electrophoresis the wet gel was transferred to filter paper (Whatman, Maidstone, UK) covered with Saran wrap and exposed to a phosphorous screen; the bands were visualized on a PhosphorImager using ImageQuaNT™ software (Molecular Dynamics, Sunnyvale, CA, USA).

PATHOLOGICAL FINDINGS

The lesion predominately consisted of perivascular pseudorosettes formed by neoplastic cells with long non-tapering cell processes centrally radiating to perivascular channels (Fig. 2a). The tumor cells were round to oval and showed brisk mitotic figures. There was marked sclerosis of the blood vessels and stroma. Several areas of necrosis and occasional vascular proliferation were encountered. Immunostainings for GFAP (Fig. 2b), S-100 protein and vimentin were positive, whereas negative results were noted on EMA and NF.

Electron microscopy showed tumor cells with well-defined cell borders (Fig. 3a). There were abundant intermediate filaments within the cytoplasm (Fig. 3b). Basal lamina were seen separating these neoplastic cells from blood vessels. The pathological diagnosis of astroblastoma was made.

The D19S412 locus was the only informative marker on the long arm of chromosome 19 that showed LOH




Fig. 2 Histopathologically, astroblastoma predominately consists of (a) perivascular pseudorosette (HE). (b) Glial fibrillary acidic protein immunostain highlights thick non-tapering cell processes radiating toward a central blood vessel (asterisk; immunoperoxidase with hematoxylin counterstain).




Fig. 3 (a) Ultrastructurally, tumor cells possess a well-demarcated cell border. (Bar = 2 μ m). (b) Abundant 6–9-nm intermediate filaments are demonstrated in the cytoplasm. (Bar = 0.5 μ m).

4b). The other microsatellite markers on chromosomes 9, 10, 11, 17 and 22 demonstrated either maintenance of both alleles or uninformative data. At least one informative locus in each chromosome, however, was tested. A representative microsatellite locus (D11S554) showing maintenance of both alleles was also depicted (Fig. 4a).

DISCUSSION

In the recent World Health Organization classification of the central nervous system tumors, astroblastomas appear in the group of neuroepithelial tumors of uncertain origin, reflecting their controversial histogenesis.¹⁰ The




Fig. 4 Autoradiographs show (a) maintenance of both alleles at D11S554 on chromosome 11p and (b) loss of the upper allele at the D19S412 locus on chromosome 19q. N, normal leukocyte DNA; T, tumor DNA.

positivity to GFAP, S-100 protein, and vimentin immunostains, together with the presence of intermediate filaments on electron microscopy and the absence of ependymal or neuronal features favor a putative astrocytic origin.² Based on an electron microscopic, immunohistochemical, tissue and organ culture study showing a glial cell with features intermediate between those of ependymocytes and astrocytes, however, the tancyte, a glial precursor cell normally found scattered along the ependymal lining of the embryonal and neonatal mammalian brain, was also considered to be the cell origin of astroblastomas.¹¹ Although the entity is not now universally accepted, a series of 17 astroblastomas showing distinct clinicopathological features has recently been described.¹⁷

A well-demarcated cystic mass with an enhancing mural nodule could be one of several lesions that have a similar radiological feature, including pilocytic astrocytoma, ganglioglioma, pleomorphic xanthoastrocytoma (PXA) and hemangioblastoma.¹³⁻¹⁶ Pilocytic astrocytomas are low-grade astrocytic neoplasms that commonly occur in childhood. Their most common locations are the midline structures including the visual system, the hypothalamus and the cerebellum, but not the cerebral hemispheres.^{13,14} Although they are frequently encountered in the cerebral hemispheres, gangliogliomas and PXA favor the temporal lobes and most patients with these tumors present with seizures.^{13,16,17} Hemangioblastomas may also demonstrate the same radiological finding but they are rare in children.^{13,15}

The histological differential diagnosis of astroblastomas include ependymomas, papillary meningiomas and diffuse astrocytomas. Ependymomas are common intraventricular tumors but occasionally occur in the brain parenchyma. The problem is more complicated by the fact that both tumors show identical immunoreactivity, being positive

for GFAP, vimentin and S-100 protein.¹⁸ Nevertheless, cytoplasmic processes in ependymoma are typically fine and taper towards central vascular channels, whereas those in astroblastoma are coarse and differ further in terminating on their target vessels as expanded footplates.^{12,18} Extensive vascular sclerosis is another finding suggestive of astroblastoma.¹⁸

Vascular cores surrounded by neoplastic cells—papillary meningiomas are distinctly similar to perivascular pseudorosettes of astroblastomas.¹⁸ Most meningiomas, however, are dural-based lesions.¹⁹ The lack of complete meningotheelial differentiation together with immunohistochemistry showing reactivity for GFAP and negativity for EMA excludes this possibility.

It should be kept in mind that diffuse astrocytomas, especially the gemistocytic variant and glioblastomas frequently contain focal areas of perivascular pseudorosettes. Therefore the diagnosis of astroblastoma should be reserved for well-demarcated gliomas that are or mainly composed of the characteristic glial structure mentioned here.^{14,18}

Electron microscopy is essential to confirm the diagnosis of astroblastoma even though there is no ultrastructural feature that can be regarded as characteristic of this entity.³ The presence of cytoplasmic intermediate filaments is a consistent finding that was also observed in the present case.^{3,19}

LOH 19q in the present study of astroblastoma suggests that there may be a tumor suppressor gene (TSG) in this chromosomal region that plays a role in astroblastoma oncogenesis. The locus D19S412 also lies among the common sites of allelic loss in diffuse astrocytomas and oligodendroglial tumors.^{6,7} Because the TSG in the short arm of chromosome 19 that is responsible for the development of these central nervous system neoplasms has not been identified, it remains to be elucidated whether these tumors are caused by mutations in the same gene. Microsatellite analysis on chromosome 1p in astroblastoma is also of interest because oligodendrogliomas frequently show LOH in this chromosomal region.⁷

A question may be raised as to whether LOH 19q in the present case is true or whether it has resulted false, an allele dropout because the tumor DNA was extracted from paraffin-embedded tissue while the constitutional DNA came from blood leukocytes. We do believe, however, that such a possibility is unlikely because a minute amount of contaminated normal tissue (e.g. endothelial cells within the tumor) was amplified, as reflected by a weak upper band in the tumor (T) lane (Fig. 4a). Both the contaminated normal and the tumor DNA were derived from the same paraffin blocks. Furthermore, it has been suggested that the incidence of allele dropout during DOP-PCR is low provided a large amount of tissue is used.²⁰

In summary, an astroblastoma is reported in a 5-year-old girl. The presence of allelic loss on the long arm of chromosome 19 indicates that this chromosomal region harbors a putative tumor suppressor gene related to astroblastoma oncogenesis.

ACKNOWLEDGMENTS

The authors thank Professor Byron A Kakulas of Royal Perth Hospital for reviewing the manuscript and the pathology of the case. This work is supported by the Molecular Biology Project, Faculty of Medicine, Chulalongkorn University, and the Thailand Research Fund.

REFERENCES

1. Bonnin JM, Rubinstein LJ. Astroblastomas: A pathological study of 23 tumors, with a postoperative follow-up in 13 patients. *Neurosurgery* 1989; **25**: 6-13.

2. Lantos PL. Astroblastoma. In: Kleihues P, Cavenee WK (eds). *Pathology and Genetics of Tumours of the Nervous System*. Lyon: International Agency for Research on Cancer, 1997; 62-63.

3. Jay V, Edwards V, Squire J, Rutka J. Astroblastoma: Report of a case with ultrastructural, cell kinetic, and cytogenetic analysis. *Pediatr Pathol* 1993; **13**: 323-332.

4. Ransom DT, Ritland SR, Moertel CA *et al*. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. *Genes Chromosomes Cancer* 1992; **5**: 357-374.

5. Ransom DT, Ritland SR, Kimmel DW *et al*. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. *Genes Chromosomes Cancer* 1992; **5**: 348-356.

6. von Deimling A. Differential patterns of molecular genetic alterations define subsets among glioblastomas and oligoastrocytomas. *Neuropathology* 1998; **18**: 145-153.

7. von Deimling A, Bender B, Jahnke R *et al*. Loci associated with malignant progression in astrocytomas:

A candidate on chromosome 19q. *Cancer Res* 1994; **54**: 1397-1401.

8. Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA, Tunnacliffe A. Degenerate oligonucleotide-primed PCR: General amplification of target DNA by a single degenerate primer. *Genomics* 1992; **3**: 718-725.

9. Mutirangura A, Charuruks N, Shuangshoti S *et al*. Identification of distinct regions of allelic loss on chromosome 13q in nasopharyngeal cancer from paraffin embedded tissues. *Int J Cancer* 1999; **83**: 210-214.

10. Kleihues P, Burger PC, Scheithauer BW. *Histology. Typing of Tumors of the Central Nervous System*. 2nd edn. Berlin: Springer-Verlag, 1993.

11. Rubinstein LJ, Herman MM. The astroblastoma and its possible cytogenic relationship to the tanyocyte. An electron microscopic, immunohistochemical, tissue- and organ- culture study. *Acta Neuropathol (Berl)* 1987; **78**: 472-483.

12. Brat DJ, Cohen KJ, Sanders JM, Feuerstein BG, Burger PC. Clinicopathologic features of astroblastoma (abstract). *J Neuropathol Exp Neurol* 1999; **58**: 509.

13. Lantos PL, Vandenberg SR, Kleihues P. Tumours of the nervous system. In: Graham DI, Lantos PL (eds). *Greenfield's Neuropathology*. Vol 2, 6th edn. London: Arnold, 1997; 583-879.

14. Osborn AG. *Diagnostic Neuroradiology*. St Louis: Mosby, 1994.

15. Ho VB, Smirniotopoulos JG, Murphy FM, Rushing EJ. Radiologic-pathologic correlation: Hemangioblastoma. *AJNR* 1992; **13**: 1343-1352.

16. Tampieri D, Moumdjian R, Melanson D, Ethier E. Intracerebral gangliogliomas in patients with partial complex seizures. CT and MR findings. *AJNR* 1991; **12**: 749-755.

17. Yoshino MT, Lucio R. Pleomorphic xanthoastrocytoma. *AJNR* 1992; **13**: 1330-1332.

18. Burger PC, Scheithauer BW. *Tumors of the Central Nervous System. Atlas of Tumor Pathology*. 3rd Series. Fascicle 10. Washington DC: Armed Forces Institute of Pathology, 1994.

19. Kubota T, Hirano A, Sato K, Yamamoto S. The fine structure of astroblastoma. *Cancer* 1985; **55**: 745-750.